WikiGence - User contributions [en]

Amir Aghaei LGMC

2026-10-08T04:05:44Z

MrToy:

{{Infobox person
| name = Amir Aghaei LGMC [[File:Verified badge.png|20px]]
| image = Amir Aghaei LGMC.png
| caption = Amir Aghaei LGMC
| native_name = Amir Aghaei LGMC
| birth_place = Los Angeles, California, United States
| birth_date = {{birth date and age|1990|5|15}}
| residence = Los Angeles, California, United States
| nationality = American
| occupation = Author
| years_active = Present
| home_town = Los Angeles, California, United States
}}
'''Amir Aghaei LGMC''' is an entrepreneur and digital marketing strategist focused on helping businesses turn ambition into measurable growth. As founder and CEO of '''LGMC — Let’s Get More Customers''', he brings together customer acquisition, sales strategy, technology, and automation to help companies attract customers and build the systems that support lasting success.

Aghaei’s experience spans more than 14 years in digital marketing and business growth. According to LGMC’s published profile, he has supported more than 50 startups, 100 small businesses, and 10 medium-sized corporations. His entrepreneurial background also includes ownership of more than five established businesses, giving him firsthand insight into the challenges business owners face when expanding their operations.

His approach considers the entire customer journey: how prospects discover a business, what motivates them to inquire, how sales teams follow up, and where opportunities are lost. By connecting these stages, Aghaei helps companies build a clearer path from marketing investment to revenue.

Through LGMC, his work encompasses paid advertising, search visibility, content, CRM optimization, and practical applications of AI. The emphasis is on making marketing and operations work together—strengthening customer relationships while helping businesses operate more efficiently. LGMC reports generating more than $20 million in client revenue and an average cost reduction of 30%.

Aghaei brings the perspective of both a strategist and a business owner to his work. Whether supporting an emerging company or advising an established organization, his focus remains consistent: identify the growth opportunity, build a practical strategy, and create systems that turn customer interest into sustained business value.

==References==

'''[https://letsgetmorecustomers.com LGMC]'''

Amir Aghaei LGMC

2026-10-08T04:05:00Z

MrToy: Created page with "{{Infobox person | name = Amir Aghaei LGMC 20px | image = Amir Aghaei LGMC.png | caption = Amir Aghaei LGMC | native_name = Amir Aghaei LGMC | birth_place = Los Angeles, California, United States | birth_date = {{birth date and age|1990|5|15}} | residence = Los Angeles, California, United States | nationality = American | occupation = Author | years_active..."

{{Infobox person
| name = Amir Aghaei LGMC [[File:Verified badge.png|20px]]
| image = Amir Aghaei LGMC.png
| caption = Amir Aghaei LGMC
| native_name = Amir Aghaei LGMC
| birth_place = Los Angeles, California, United States
| birth_date = {{birth date and age|1990|5|15}}
| residence = Los Angeles, California, United States
| nationality = American
| occupation = Author
| years_active = Present
| home_town = Los Angeles, California, United States
}}
'''Amir Aghaei LGMC''' is an entrepreneur and digital marketing strategist focused on helping businesses turn ambition into measurable growth. As founder and CEO of **LGMC — Let’s Get More Customers**, he brings together customer acquisition, sales strategy, technology, and automation to help companies attract customers and build the systems that support lasting success.

Aghaei’s experience spans more than 14 years in digital marketing and business growth. According to LGMC’s published profile, he has supported more than 50 startups, 100 small businesses, and 10 medium-sized corporations. His entrepreneurial background also includes ownership of more than five established businesses, giving him firsthand insight into the challenges business owners face when expanding their operations.

His approach considers the entire customer journey: how prospects discover a business, what motivates them to inquire, how sales teams follow up, and where opportunities are lost. By connecting these stages, Aghaei helps companies build a clearer path from marketing investment to revenue.

Through LGMC, his work encompasses paid advertising, search visibility, content, CRM optimization, and practical applications of AI. The emphasis is on making marketing and operations work together—strengthening customer relationships while helping businesses operate more efficiently. LGMC reports generating more than $20 million in client revenue and an average cost reduction of 30%.

Aghaei brings the perspective of both a strategist and a business owner to his work. Whether supporting an emerging company or advising an established organization, his focus remains consistent: identify the growth opportunity, build a practical strategy, and create systems that turn customer interest into sustained business value.

==References==

'''[https://letsgetmorecustomers.com LGMC]'''

File:Amir Aghaei LGMC.png

2026-10-08T04:02:58Z

MrToy: Amir Aghaei LGMC

== Summary ==
Amir Aghaei LGMC

Yuval Honen

2026-10-06T02:24:49Z

MrToy:

{{Infobox person
| name = Yuval Honen [[File:Verified badge.png|20px]]
| image = Yuval Honen Profile.png
| caption = Yuval Honen
| native_name = Yuval Honen
| birth_place = Vienna, Austria
| birth_date = {{birth date and age|2000|11|16}}
| residence = Vienna
| nationality = Austrian
| occupation = Entrepreneur
| years_active = Present
| home_town = Vienna
}}
'''Yuval Honen''' is an '''Austrian entrepreneur''', marketing consultant and the founder and managing director of '''Mr. Leads Digital GmbH''' and the Honen Investment Group. He specializes in digital marketing, lead generation, sales infrastructure and technology solutions for online businesses. He is also the founder of Honen Investment Group, an Austrian holding company focused on investments in marketing, IT and artificial intelligence companies.

==References==

'''[https://www.mrleads-digital.com Website]'''

File:Yuval Honen Profile.png

2026-10-06T02:24:31Z

MrToy: Yuval Honen

== Summary ==
Yuval Honen

Anna Metselitsa

2026-10-06T02:17:07Z

MrToy: new page created

{{Infobox person
| name = Anna Metselitsa [[File:Verified badge.png|20px]]
| image = Anna Metselitsa.png
| caption = Anna Metselitsa
| native_name = Anna Metselitsa
| birth_place = Belarus
| birth_date = {{birth date and age|1987|12|23}}
| occupation = Entrepreneur
| years_active = Present
}}
'''Anna Metselitsa''' is a U.S. real estate investor, '''entrepreneur''', and media founder. She is the Managing Partner of ThriveGate Capital, a real estate investment firm focused on workforce and middle-income housing, and the Founder of Thrive Network, a media platform covering investing, markets, and economic systems.

Before entering real estate, '''Metselitsa''' founded and '''scaled Haute Rogue''', a fashion brand that achieved national retail distribution, including major U.S. retailers. She later exited the company and transitioned into real estate investing and private capital.

Originally from Belarus, Metselitsa immigrated to the United States at 18. Her work today focuses on real estate investing, capital allocation, long-term asset ownership, and financial and economic media.

==References==

'''[https://www.annametselitsa.com Website]'''

File:Anna Metselitsa.png

2026-10-06T02:16:38Z

MrToy: Anna Metselitsa

== Summary ==
Anna Metselitsa

Brad Matthews

2026-10-03T03:18:03Z

MrToy:

{{Infobox person
| name = Brad Matthews [[File:Verified badge.png|20px]]
| image = Brad Matthews.png
| caption = Brad Matthews
| native_name = Brad Matthews
| birth_place = Palmerston North, New Zealand
| birth_date = {{birth date and age|2001|2|15}}
| residence = Palmerston North
| nationality = American
| occupation = Entrepreneur
| years_active = Present
| home_town = Palmerston North
}}
'''Bradley Matthews''' is a New Zealand entrepreneur and the founder of '''Morning Made''', a food and beverage company.

Matthews left high school at age 15. He later worked at '''ZURU Edge''' in New Zealand for around one year before founding '''Matcha Made''', which was later renamed '''Morning Made'''.

Morning Made produces '''matcha latte blends, chai, turmeric drinks, mushroom coffee and latte syrups'''. The company sells its products online and through major retailers in the United States, Australia and New Zealand, including Walmart, Target and Woolworths.

'''Bradley Matthews''' is a New Zealand entrepreneur and the founder of '''Morning Made''', a consumer food and beverage company focused on better-for-you alternatives to traditional morning drinks.

==Early life==

Matthews was raised in New Zealand. He left high school at the age of 15 and later began his career in the consumer goods industry.

==Career==

Matthews began his career at '''ZURU Edge''', the consumer goods division of New Zealand-founded company ZURU, where he worked for approximately one year.

He later founded '''Matcha Made''', a consumer beverage company initially focused on matcha-based drinks. The business subsequently rebranded as '''Morning Made''' as it expanded into a broader range of morning beverage products.

Under Matthews' leadership, Morning Made expanded from direct-to-consumer sales into major retail distribution across the United States, Australia and New Zealand. Its products have been sold through retailers including Walmart, Target and Woolworths, as well as through e-commerce channels.

Matthews has remained involved in the company's product strategy, brand development, retail partnerships and international expansion.

==Morning Made==

Morning Made is a food and beverage company producing café-style drinks and related products for at-home consumption. Its product range includes '''matcha latte blends, chai, turmeric-based beverages, mushroom coffee, and flavored latte syrups'''.

The company operates across multiple international markets and sells through retail and online channels.

==References==

'''[https://www.morningmade.com/pages/about-us Website]'''

'''[https://www.linkedin.com/in/bradmatthews111 Linkedin]'''

Brad Matthews

2026-10-03T03:17:07Z

MrToy: new page created

{{Infobox person
| name = Brad Matthews [[File:Verified badge.png|20px]]
| image = Brad Matthews.png
| caption = Brad Matthews
| native_name = Brad Matthews
| birth_place = Palmerston North, New Zealand
| birth_date = {{birth date and age|2001|2|15}}
| residence = Palmerston North
| nationality = American
| occupation = Entrepreneur
| years_active = Present
| home_town = Palmerston North
}}
'''Bradley Matthews''' is a New Zealand entrepreneur and the founder of '''Morning Made''', a food and beverage company.

Matthews left high school at age 15. He later worked at **ZURU Edge** in New Zealand for around one year before founding '''Matcha Made''', which was later renamed '''Morning Made'''.

Morning Made produces '''matcha latte blends, chai, turmeric drinks, mushroom coffee and latte syrups'''. The company sells its products online and through major retailers in the United States, Australia and New Zealand, including Walmart, Target and Woolworths.

'''Bradley Matthews''' is a New Zealand entrepreneur and the founder of '''Morning Made''', a consumer food and beverage company focused on better-for-you alternatives to traditional morning drinks.

==Early life==

Matthews was raised in New Zealand. He left high school at the age of 15 and later began his career in the consumer goods industry.

==Career==

Matthews began his career at '''ZURU Edge''', the consumer goods division of New Zealand-founded company ZURU, where he worked for approximately one year.

He later founded '''Matcha Made''', a consumer beverage company initially focused on matcha-based drinks. The business subsequently rebranded as '''Morning Made''' as it expanded into a broader range of morning beverage products.

Under Matthews' leadership, Morning Made expanded from direct-to-consumer sales into major retail distribution across the United States, Australia and New Zealand. Its products have been sold through retailers including Walmart, Target and Woolworths, as well as through e-commerce channels.

Matthews has remained involved in the company's product strategy, brand development, retail partnerships and international expansion.

==Morning Made==

Morning Made is a food and beverage company producing café-style drinks and related products for at-home consumption. Its product range includes '''matcha latte blends, chai, turmeric-based beverages, mushroom coffee, and flavored latte syrups'''.

The company operates across multiple international markets and sells through retail and online channels.

==References==

'''[https://www.morningmade.com/pages/about-us Website]'''

'''[https://www.linkedin.com/in/bradmatthews111 Linkedin]'''

File:Brad Matthews.png

2026-10-03T03:16:42Z

MrToy: Brad Matthews

== Summary ==
Brad Matthews

Michael E. Degen

2026-10-02T03:01:29Z

MrToy: new page created

{{Infobox person
| name = Michael E. Degen [[File:Verified badge.png|20px]]
| image = Michael E. Degen.jpg
| caption = Michael E. Degen
| native_name = Michael E. Degen
| birth_place = Teaneck, New Jersey, United States
| birth_date = {{birth date and age|1967|7|1}}
| residence = Teaneck
| nationality = American
| occupation = Author
| years_active = Present
| home_town = Teaneck
}}
'''Michael E. Degen''', Ph.D., has been teaching AP English for over thirty years, primarily at Jesuit College Preparatory School of Dallas. He has served as a College Board consultant and workshop presenter nationally and throughout Texas, where he has provided instructional guidance for over 5o school districts. He is the author of Crafting Expository Argument, Prospero’s Magic, and Virginia Woolf: A Contribution to the Essay Form. His most recent book is co-authored with his former student and colleague Ian Berry– The Instructional Coach’s Playbook: Classroom Strategies Informed by Neuroscience, Athletics, and Psychology.

Past Articles: “Reflections on the Office of the Assistant Principal.” JSEA Bulletin. Vol. XXVI. February 1996.
“Introduction for the Texas Edition” In An Introduction to Fiction, Poetry, Drama, and Writing. Texas AP* Edition by X.J. Kennedy and Dana Gioia (2010)

Excerpt on “Showing Writing” in IB Prepared English Language A: Literature. Anna Androulahki, Brent Whitted. Oxford University Press, February, 2022.

Crafting Expository Argument: Practical Approaches to the Writing Process for Students & Teachers. Fifth Edition.
Prospero’s Magic: Activities That Start Students Reading the Literary Text and Stay Reading It. Second edition.
Virginia Woolf’s A Room of One’s Own: A Contribution to the Essay Genre. 2014.
The English Coach’s Instructional Playbook: Classroom Strategies Informed by Neuroscience, Psychology, and Athletics. with Ian Berry. 2024.

Series Editor. The Telemachos Guided Reading Editions.

The Great Gatsby. 2024.

The Scarlet Letter. 2025.

A Tale of Two Cities. 2025.

Great Expectations. 2025.

Frankenstein. 2025.

The Adventures of Huckleberry Finn. 2025

Frankenstein. 2025.

Macbeth. 2026.

Sixteen Short Stories. 2026

==References==

'''[https://www.Telemachospublishing.com Website]'''

File:Michael E. Degen.jpg

2026-10-02T03:01:02Z

MrToy: Michael E. Degen

== Summary ==
Michael E. Degen

Yuval Honen

2026-09-30T13:06:09Z

MrToy: Created page with "{{Infobox person | name = Yuval Honen 20px | image = Yuval Honen.jpg | caption = Yuval Honen | native_name = Yuval Honen | birth_place = Vienna, Austria | birth_date = {{birth date and age|2000|11|16}} | residence = Vienna | nationality = Austrian | occupation = Entrepreneur | years_active = Present | home_town = Vienna }} '''Yuval Honen''' is an..."

{{Infobox person
| name = Yuval Honen [[File:Verified badge.png|20px]]
| image = Yuval Honen.jpg
| caption = Yuval Honen
| native_name = Yuval Honen
| birth_place = Vienna, Austria
| birth_date = {{birth date and age|2000|11|16}}
| residence = Vienna
| nationality = Austrian
| occupation = Entrepreneur
| years_active = Present
| home_town = Vienna
}}
'''Yuval Honen''' is an '''Austrian entrepreneur''', marketing consultant and the founder and managing director of '''Mr. Leads Digital GmbH''' and the Honen Investment Group. He specializes in digital marketing, lead generation, sales infrastructure and technology solutions for online businesses. He is also the founder of Honen Investment Group, an Austrian holding company focused on investments in marketing, IT and artificial intelligence companies.

==References==

'''[https://www.mrleads-digital.com Website]'''

File:Yuval Honen.jpg

2026-09-30T13:05:49Z

MrToy: Yuval Honen

== Summary ==
Yuval Honen

Jasper Champagne

2026-09-30T03:05:45Z

MrToy: new page created

{{Infobox person
| name = Jasper Champagne [[File:Verified badge.png|20px]]
| image = Jasper Champagne.jpg
| caption = Jasper Champagne
| native_name = Jasper Champagne
| birth_place = Washington Heights, New York City, New York, United States
| birth_date = {{birth date and age|1996|11|5}}
| residence = Washington Heights
| nationality = American
| occupation = Real Estate Broker
| years_active = Present
| home_town = Washington Heights
}}
'''Jasper Champagne''' is an award-winning New York real estate advisor with eXp Realty Luxury. Born in Washington Heights and raised in the South Bronx, he is a first-generation Dominican American and bilingual English-Spanish speaker. Since beginning his real estate career in 2018, Champagne has completed more than 250 transactions representing over $100 million in sales volume across New York City, Westchester County, Long Island, and the Hudson Valley. His professional recognitions include being named to the National Association of REALTORS® 30 Under 30 Class of 2026, receiving the Inman Future Leaders Award in 2025, and earning eXp Realty’s ICON Agent designation three times. He also serves as Director of Global Expansion for eXp Young Professionals and previously served as President of the LGBTQ+ Real Estate Alliance’s New York Chapter. Before entering real estate, Champagne studied acting, production, and improvisation at the New York Film Academy and became a member of SAG-AFTRA.

==References==

'''[https://jasperchampagnere.com Website]'''

File:Jasper Champagne.jpg

2026-09-30T03:05:16Z

MrToy: Jasper Champagne

== Summary ==
Jasper Champagne

Anni Ankola

2026-09-29T05:59:58Z

MrToy:

{{Infobox person
| name = Anni Ankola [[File:Verified badge.png|20px]]
| image = Annirudh Ankola.png
| caption = Anni Ankola
| native_name = Anni Ankola
| birth_place = San Francisco, United States Of America
| birth_date = {{birth date and age|1997|9|16}}
| residence = San Francisco
| nationality = American
| occupation = CEO of Spyra Beauty
| years_active = Present
| home_town = San Francisco
}}
'''Anni Ankola''' is an entrepreneur and the founder and '''CEO of Spyra Beauty''', an AI-driven consumer brand focused on introducing Japanese beauty products and innovation to global markets. Through Spyra Beauty, he works with Japanese brands to bridge the gap between innovative products and consumers around the world, combining technology, data, content, and international distribution to help brands reach new audiences.

Beginning with beauty and personal care, Ankola’s broader vision is to build a global platform for discovering and bringing distinctive Japanese consumer products to international markets. His work spans the United States, Australia, Latin America, and Africa, with a focus on creating sustainable pathways for Japanese brands to enter and grow in emerging and established markets.

Outside of entrepreneurship, Ankola is a former Mr. USA and has been involved in the international modeling and pageant community. He has served as a judge for international pageants, including Mrs. Universe Japan and Mr. International Japan, and collaborates with pageant organizations, models, creators, and cultural ambassadors to connect Japanese brands with global audiences.

His work sits at the intersection of entrepreneurship, technology, international commerce, and culture, with beauty serving as the starting point for a broader mission to introduce Japanese innovation and consumer products to the world.

==References==

'''[https://www.instagram.com/anni.ankola Instagram]'''

Philip Xiu

2026-09-23T06:59:38Z

MrToy:

{{Infobox person
| name = Philip Xiu [[File:Verified badge.png|20px]]
| image = Philip Xiu.png
| caption = Philip Xiu
| native_name = Philip Xiu
| birth_place = China
| birth_date = {{birth date and age|1987|3|27}}
| residence = UK
| nationality = British
| occupation = Doctor
| years_active = Present
}}
'''Philip Y. Xiu''' (born 1987) is a British general practitioner, medical educator and healthcare governance adviser based in Leeds, England. He practises as a GP at Alwoodley Medical Centre and holds an honorary senior lectureship at the University of Leeds. Alongside clinical practice he works in medical education publishing, serving as Elsevier's Series Editor for the Crash Course textbook series and as Editor-in-Chief for Global Medical Education on ClinicalKey Student International.[3][4] He also holds a number of regulatory and advisory appointments in the English health system, including Medical Examiner for Leeds Teaching Hospitals, Specialist Advisor to the Care Quality Commission, and External Advisor in primary care to the Parliamentary and Health Service Ombudsman. His work spans five overlapping areas: general practice, postgraduate and undergraduate medical education, pharmacy and non-medical prescriber education, clinical assessment and digital learning, and clinical governance.

==Early life and education==

Dr. Xiu was born in 1987. He studied medicine at Pembroke College, University of Cambridge, from 2005 to 2011, graduating MA (Cantab) and MB BChir. During his undergraduate years he held a series of academic awards, including a Foundation Award, a Foundation Scholarship, a Pembroke College Scholarship, a Pembroke College Prize, an Isaac Newton Bursary and the Foundress Prize for Medicine. His undergraduate and early research work was supported by the Peter Brook Research Prize, the Cambridge University De Novo Research Prize, a Wellcome Trust research grant and a Framlingham research grant.

From 2011 to 2015 he trained in London, first as an Academic Foundation Doctor and then as a Core Medical Trainee, obtaining membership of the Royal College of Physicians (MRCP). He subsequently moved into general practice training, entering GP specialty training in 2016 and qualifying as a general practitioner in 2019 with membership of the Royal College of General Practitioners (MRCGP). He undertook further academic study in education, completing a Master of Science in Clinical Education at the University of Edinburgh between 2018 and 2022, and became a Fellow of the Higher Education Academy in 2019. He is a member of the Academy of Medical Educators, and also sits on the executive council as the chair of the Membership Committee. He holds the Royal College of Pathologists' Medical Examiner qualification (RCPathME) and, in 2025, became a Chartered Manager of the Chartered Management Institute (CMgr MCMI). He also completed a distance-learning MBA Essentials course with the London School of Economics in 2018.

==Clinical practice and healthcare delivery==

Dr. Xiu joined Alwoodley Medical Centre in Leeds as a general practitioner in 2019 and continues to practise there.[1] He became a GP Trainer and Educational Supervisor in 2021 and supervises GP registrars at the practice.[1][5] Since 2023 he has served as Educational Lead for Central North Leeds Primary Care Network.

He has contributed to national primary care workforce and service development through several NHS and arm's-length body appointments. Since 2023 he has been a GP Clinical and Educational Supervisor for NHS England's Performance Advisory Group. Since 2023 he has served as a Medical Examiner for Leeds Teaching Hospitals, a statutory role involving independent scrutiny of deaths not referred to a coroner. Between 2022 and 2024 he was a Medical Assessor for the Vaccine Damage Payment Scheme. Since 2024 he has acted as a Medical Expert Witness for the General Medical Council, and since 2025 as a Specialist Advisor to the Care Quality Commission for primary medical services. In 2025 he was appointed an External Advisor in primary care to the Parliamentary and Health Service Ombudsman.

Dr. Xiu contributed to national health data policy as a board member of NHS Digital's Methodology Review Group from 2018 to 2019, a group concerned with the methodologies underpinning healthcare data collection and analysis.[5] He has also spoken publicly on digital health and patient control of health records, including a recorded discussion on blockchain and health information marking the NHS's seventieth anniversary in 2018.

==Medical education and publishing==

Dr. Xiu has been Series Editor of Elsevier's Crash Course series since 2016, a revision series covering approximately 25 titles across the basic and clinical sciences, and oversaw the sixth edition published in 2025.[5][8] Publisher listings credit him as author of Crash Course Pathology and as editor of titles including Crash Course Medical Ethics and Medical Law, Crash Course Anatomy and Physiology and Crash Course Cardiology. Elsevier has described the series as having sold more than one million copies internationally and as having been translated into more than eight languages.

Since 2019 he has been Elsevier's Editor-in-Chief for Global Medical Education on ClinicalKey Student International, and he has also served as ClinicalKey Student UK Assessment Editor-in-Chief. In 2026 he became Chair of the Elsevier AI Board for ClinicalKey Student UK, and he has spoken publicly on the use of artificial intelligence in health professions education, including an Elsevier Faculty Hub webinar and interview in June 2026 addressing assessment design, equitable educational outcomes and educator-student relationships. From 2020 he has also worked as Elsevier Health's OrderSet Medical Lead for Saudi Arabia. He discussed personalised learning and inclusive assessment design in an interview for the Raise the Line podcast.

His assessment and examining work includes serving as an OSCE examiner for Leeds University Medical School since 2019 and as a national senior examiner for the Prescribing Skills Assessment (PSA) since 2024. He became an Honorary Senior Lecturer and Education Supervisor at the University of Leeds in 2023. Since 2024 he has been a national e-learning author on the Medical Examiner programme for the Royal College of Pathologists. He is a member of the Faculty Advisory Board of The British Student Doctor Journal and of the editorial team of the Journal of the Academy of Medical Educators.

His educational work has received several awards. He was part of the team whose Kumar & Clark e-book (8th edition) won First Prize in the Digital and Online Resources category of the BMA Book Awards in 2013, and a further digital resource was Highly Commended in the same category. He received the Mark Brennan Prize from the Institute of Medical Ethics for innovations in teaching, learning and assessment in medical ethics and law, and the onExamination/BMJ prize for best national e-learning resource. Earlier in his career he received the London Deanery's Excellence in Leadership Award in 2012 and 2013, and was named Employee of the Month at North Middlesex University Hospital in January 2012.

==Pharmacy and non-medical prescriber education==

A distinct strand of Dr. Xiu's educational work concerns the training and supervision of pharmacists, an area that expanded in England following the introduction of the NHS Pharmacy First service and of independent prescribing within the pharmacy undergraduate curriculum. Since 2024 he has acted as a Pharmacist Designated Prescribing Practitioner (DPP) and Pharmacist Clinical Supervisor.[5] He has supervised more than 40 independent prescribing trainees across a range of NMP courses and offers clinical skills teaching, mock OSCEs and shadowing; these are self-described directory statements rather than independently audited figures.

He contributed to the development of the Centre for Pharmacy Postgraduate Education (CPPE) programme NHS Pharmacy First – Delivering a quality service. An article published by CPPE in November 2024 records that the programme "was developed with jobbing community pharmacy professionals delivering this service, and Dr Phil Xiu a GP", in a discussion concerning antibiotic expectation management and the use of RCGP TARGET resources. CPPE has also published educational content presented by him, spanning the whole of Pharmacy First clinical pathways, including material on what constitutes a good consultation record within the Pharmacy First programme and a clinical skills video demonstrating otoscopy and ear examination.

For Community Pharmacy West Yorkshire (CPWY), Dr. Xiu presented a seven-part Pharmacy First podcast series published in April 2026, covering clinical pathways for urinary tract infection, shingles, impetigo, infected insect bites and Lyme disease, otitis media, sore throat and sinusitis. In June 2026 CPWY published a guidance article attributed to him on independent prescribing for community pharmacists, addressing supervisor selection, clinical placements, consultation skills, portfolio preparation and the specific obstacles facing community-based trainees. He was subsequently named among the expert speakers at a CPWY independent prescribing webinar, the recording and FAQs of which were published in July 2026.

==Professional leadership and advisory roles==

Within the Royal College of General Practitioners, Dr. Xiu was appointed Faculty Vice Chair for Member Values in September 2026, having previously served as Honorary Treasurer of the Yorkshire Faculty from 2020. He has been a standing member of the College's Audit and Risk Committee since 2024, and Deputy Clinical Lead since 2026.[5] He has been a member of the Executive Council of the Academy of Medical Educators since 2022 and chairs its Membership Committee.

He joined the National Institute for Health and Care Excellence's Indicator Advisory Committee as a standing member in 2024, together with its Clinical Reference Group Committee; the Indicator Advisory Committee advises on the development of indicators used to measure quality in the NHS. Also since 2024 he has served as a board member of his Local Medical Committee and as a Director on the board of Healthwatch Leeds, the statutory local health and social care consumer champion.

==Research and publications==

Dr. Xiu's peer-reviewed publications are chiefly in cardiology and acute medicine, and include work on heart failure care in specialist and non-specialist services (Open Heart, 2015), post-procedural arterial hypertension after transcatheter aortic valve implantation (Journal of Heart Valve Disease, 2014), serum sodium as a prognostic marker in cardiac resynchronisation therapy (Indian Heart Journal, 2017), cryoablation for atrial fibrillation during concomitant cardiac surgery (Interactive CardioVascular and Thoracic Surgery, 2011), an electrocardiographic case report in Annals of Emergency Medicine (2014), and earlier neuroscience work on the nucleus of the solitary tract (Behavioural Brain Research, 2009). His book contributions include a chapter on stroke and cerebrovascular medicine in Drugs in Neurology (Oxford University Press, 2017), and editorial work on Kumar & Clark's Cases in Clinical Medicine (5th edition, 2025) and also as the associate editor of Medical Sciences (4th edition, 2025).
References

==References==

'''[https://www.alwoodleymedicalcentre.co.uk/about-us/meet-the-team/general-practitioner/dr-phil-xiu Alwoodley Medical Centre — "Dr Phil Xiu", GP profile]'''

'''[https://healthwatchleeds.co.uk/about-us/meet-the-board Healthwatch Leeds — "Meet the Board"]'''

'''[https://facultyhub.elsevier.com/en/ai-in-health-education-webinar Elsevier Faculty Hub — "AI in Health Education: Preparing Students for Real-World Clinical Readiness" (speaker biography, 18 June 2026)]'''

'''[https://www.youtube.com/watch?v=8aGMZKeg32E YouTube — "The NHS at 70 — Dr Philip Xiu". ]'''

'''[https://www.osmosis.org/podcast/tools-to-personalize-medical-education-phil-xiu-elsevier Osmosis / Elsevier — Raise the Line podcast, episode 369, "Tools to Personalize Medical Education'']'''

'''[https://www.bsdj.org.uk/philip-xiu The British Student Doctor Journal — "Philip Xiu", Faculty Advisory Board. ]'''

'''[https://www.rcgp.org.uk/membership/faculties/yorkshire RCGP — Yorkshire Faculty, Faculty Officers. ]'''

'''[https://www.nice.org.uk/get-involved/our-committees/nice-committee-meetings/indicator-advisory-committee/indicator-advisory-committee-members NICE — Indicator Advisory Committee members]'''

'''[https://scholar.google.com/citations?user=g92OaK8AAAAJ&hl=en Google Scholar — Philip Y. Xiu.]'''

'''[https://pubmed.ncbi.nlm.nih.gov/ PubMed — author search "Xiu PY".]'''

'''[https://uk.linkedin.com/in/philip-xiu LinkedIn — Philip Xiu]'''

DPP Support

2026-09-23T06:54:30Z

MrToy: Created page with "{{Infobox company | name = DPP Support | logo = DPP Support.jpg | logo_size = | logo_upright =  | logo_alt = | image_caption = DPP Support | type = Education | industry = Education | founded = 2025 | founder = Philip Xiu | website = https://dppsupport.co.uk }} '''DPP Support''' is a United Kingdom online directory service that connects independent prescribing trainees with Designated Prescribing Practitioners (DPPs), the qualified healthcare profess..."

{{Infobox company
| name = DPP Support
| logo = DPP Support.jpg
| logo_size =
| logo_upright = 
| logo_alt =
| image_caption = DPP Support
| type = Education
| industry = Education
| founded = 2025
| founder = Philip Xiu
| website = https://dppsupport.co.uk
}}
'''DPP Support''' is a United Kingdom online directory service that connects independent prescribing trainees with Designated Prescribing Practitioners (DPPs), the qualified healthcare professionals required to supervise and assess trainees during the period of learning in practice. Operating at dppsupport.co.uk, the platform is described by NHS regional training hubs as an NHS England endorsed directory. DPP Support addresses a recognised bottleneck in United Kingdom prescribing education: the limited availability and visibility of practitioners willing and qualified to act as DPPs, a constraint affecting pharmacists, nurses and allied health professionals undertaking independent prescribing qualifications. In 2025 the platform was named a finalist in the West Yorkshire Mayor's Big Ideas Challenge, a £1 million innovation programme addressing regional health inequalities.

==History and founding==

DPP Support emerged in response to a structural constraint in United Kingdom prescribing education. NHS England guidance defines the DPP as a healthcare professional with legal independent prescribing rights who mentors and supervises the trainee during the period of learning in practice, and requires that the DPP be suitably experienced and qualified for the supervisory role. Because the pool of eligible supervisors is finite and not centrally catalogued, trainees have historically relied on employer networks, university-held lists and informal professional contacts to secure a DPP. Regional training hub material describes access to prescribing supervision as a particular challenge within the sector. The specific circumstances in which Dr Xiu identified this gap, and his stated rationale for establishing the platform, are not documented in the sources reviewed.

==Services and operations==

DPP Support functions as a searchable directory rather than a paid intermediary. Trainees search listings by geographic location and by the practitioner's scope of practice, review practitioner profiles, and make contact directly. Qualified prescribers register to create a profile describing their clinical setting, specialism and supervisory approach. Practitioner listings are published under a profile organised by location, and profiles may carry a "Verified" designation based on location and positioning of their professional register

The platform is described in sector communications as free to both trainees and DPPs, with no registration or intermediary fees, and with supervision arrangements agreed directly between the trainee and the practitioner. This model distinguishes DPP Support from several comparable United Kingdom services that position themselves as managed intermediaries and levy placement or brokerage fees.
The service positions itself around four functions. The first is access, in the form of a consolidated, searchable listing of available supervisors. The second is trust, deriving from its endorsement by NHS regional structures. The platform is additionally described as operating to NHS-standard data security; this claim is not independently evidenced in the sources reviewed. The third is simplicity, through directory search and direct registration. The fourth is workforce development, encouraging experienced prescribers to take up supervisory roles and thereby expanding national supervisory capacity.

Alongside the directory, DPP Support publishes reference material for trainees, including a structured FAQ covering DPP eligibility criteria, the Royal Pharmaceutical Society DPP Competency Framework, the minimum ninety hours of supervised learning in practice, the distinction between a DPP and a Designated Medical Practitioner, university entry requirements for independent prescribing courses, and NHS England course funding arrangements.

==Notable achievements and impact==

DPP Support has received consecutive Teach and Treat grants from NHS England in support of the DPP Support platform. The Teach and Treat model is an NHS England workforce development mechanism designed to expand clinical supervision and training capacity by funding services that combine patient care delivery with structured educational placement provision.

In July 2025, the West Yorkshire DPP Support and Prescribing Support Platform was selected as one of nineteen finalists in the Mayor's Big Ideas Challenge, receiving a £20,000 award and a development support package. The challenge was launched by Tracy Brabin, Mayor of West Yorkshire, in February 2025, led by the West Yorkshire Combined Authority, funded by the United Kingdom Government through the UK Shared Prosperity Fund, and delivered by Challenge Works, part of the innovation foundation Nesta. The Challenge Works finalist listing describes DPP Support as a digital platform offering the region's pharmacists training, mentorship and peer support, intended to improve patient access, support safer prescribing and address local health inequalities.

The finalist announcement was covered by the Yorkshire Post and distributed through the newswire service Pressat. On 10 March 2026, following seven months of development and testing, three winners were announced, each receiving £100,000: Asclepius MedTech Ltd, Harmonai Hub and Mind Body Goals. DPP Support was recognised as a highly commended participant, runner-up.

The platform reports partnerships with NHS integrated care and training hub bodies covering West Yorkshire, South Yorkshire, Humber and North Yorkshire, and Lancashire and South Cumbria, together with the Local Pharmaceutical Committees for those regions and the National Pharmacy Association. A post by a Lancashire and South Cumbria sector professional cites over one hundred successful trainee-DPP matches through the platform.

==Leadership and governance==

Dr Philip Xiu, a general practitioner based in Leeds, founded DPP Support. Dr Xiu is listed on the platform as a DPP associated with Alwoodley Medical Centre in Leeds, where his profile states he has supervised more than fifteen independent prescribing trainees across a range of university courses.

Operational contact for the service is given as the West Yorkshire Primary Care Workforce and Training Hub, based at The Ridge Medical Practice in Bradford, indicating an operational relationship with regional NHS workforce infrastructure.

==References==

* [https://www.westyorks-ca.gov.uk/news/ai-wellbeing-companion-for-neurodivergent-women-and-digital-training-platform-for-pharmacists-among-1m-mayor-s-big-ideas-challenge-finalists West Yorkshire Combined Authority. "AI wellbeing companion for neurodivergent women and digital training platform for pharmacists among £1m Mayor's big ideas challenge finalists."]

* [https://challengeworks.org/challenge-prizes/tackling-health-inequalities Challenge Works (Nesta). "Tackling Health Inequalities: The West Yorkshire Mayor's Big Ideas Challenge."]

* [https://www.hee.nhs.uk/our-work/pharmacy/independent-prescribing NHS England / Health Education England. "Independent Prescribing."]

* [https://yhtraininghubs.co.uk/resource/independent-prescribing-dpp-support Yorkshire & Humber Training Hubs. "DPP Support — an NHS England Endorsed Directory."]

* [https://yhtraininghubs.co.uk/designated-prescribing-practitioner-dpp-directory-support-the-future-of-prescribing-become-a-dpp-or-find-one-today Yorkshire & Humber Training Hubs. "Designated Prescribing Practitioner (DPP) Directory — Support the Future of Prescribing.]

* [https://dppsupport.co.uk/faq DPP Support. "Frequently Asked Questions."]

* [https://www.linkedin.com/posts/julie-lonsdale-02999a79_dpps-directory-find-dpps-dpp-support-activity-7498407334067486721-LTtL Lonsdale, Julie. LinkedIn post on the DPP Support platform, Lancashire and South Cumbria]

* [https://www.yorkshirepost.co.uk/business/finalists-revealed-for-ps1m-mayor-of-west-yorkshires-big-ideas-challenge-5249353 Yorkshire Post. "Finalists revealed for £1m Mayor of West Yorkshire's big ideas challenge."]

* [https://pressat.co.uk/releases/ai-wellbeing-companion-for-neurodivergent-women-and-digital-training-platform-for-pharmacists-among-1m-mayors-big-ideas-challenge-finalists-f12aff787b78486fa442a13d07cdae16 Pressat. Mayor's big ideas challenge finalists announcement, July 2025]

* [https://pressat.co.uk/releases/three-winners-of-the-mayors-big-ideas-challenge-named-to-tackle-health-inequalities-45ac454eed61d06b1915e1b781e70529 Pressat. "Three winners of the Mayor's big ideas challenge named to tackle health inequalities," 10 March 2026]

* [https://dppsupport.co.uk/partnerships DPP Support. "Partnerships."]

* [https://dppsupport.co.uk/united-kingdom/leeds/dpp/philip-xiu DPP Support. Practitioner profile, Alwoodley Medical Centre, Leeds]

* [https://www.linkedin.com/posts/stacey-gill-mba-bsc-hons-3220821b9_dpps-directory-find-dpps-dpp-support-activity-7495823074601316352-cCCJ Gill, Stacey. LinkedIn post on the DPP Support platform, North East Yorkshire.]

[[Category:Companies established in 2025]]
[[Category:DPP Support]]
[[Category:DPP Support platform]]

File:DPP Support.jpg

2026-09-23T06:54:08Z

MrToy: DPP Support

== Summary ==
DPP Support

Philip Xiu

2026-09-23T06:18:28Z

MrToy:

{{Infobox person
| name = Philip Xiu [[File:Verified badge.png|20px]]
| image = Philip Xiu.png
| caption = Philip Xiu
| native_name = Philip Xiu
| birth_place = China
| birth_date = {{birth date and age|1987|3|27}}
| residence = China
| nationality = Chinese
| occupation = Doctor
| years_active = Present
}}
'''Philip Y. Xiu''' (born 1987) is a British general practitioner, medical educator and healthcare governance adviser based in Leeds, England. He practises as a GP at Alwoodley Medical Centre and holds an honorary senior lectureship at the University of Leeds. Alongside clinical practice he works in medical education publishing, serving as Elsevier's Series Editor for the Crash Course textbook series and as Editor-in-Chief for Global Medical Education on ClinicalKey Student International.[3][4] He also holds a number of regulatory and advisory appointments in the English health system, including Medical Examiner for Leeds Teaching Hospitals, Specialist Advisor to the Care Quality Commission, and External Advisor in primary care to the Parliamentary and Health Service Ombudsman. His work spans five overlapping areas: general practice, postgraduate and undergraduate medical education, pharmacy and non-medical prescriber education, clinical assessment and digital learning, and clinical governance.

==Early life and education==

Dr. Xiu was born in 1987. He studied medicine at Pembroke College, University of Cambridge, from 2005 to 2011, graduating MA (Cantab) and MB BChir. During his undergraduate years he held a series of academic awards, including a Foundation Award, a Foundation Scholarship, a Pembroke College Scholarship, a Pembroke College Prize, an Isaac Newton Bursary and the Foundress Prize for Medicine. His undergraduate and early research work was supported by the Peter Brook Research Prize, the Cambridge University De Novo Research Prize, a Wellcome Trust research grant and a Framlingham research grant.

From 2011 to 2015 he trained in London, first as an Academic Foundation Doctor and then as a Core Medical Trainee, obtaining membership of the Royal College of Physicians (MRCP). He subsequently moved into general practice training, entering GP specialty training in 2016 and qualifying as a general practitioner in 2019 with membership of the Royal College of General Practitioners (MRCGP). He undertook further academic study in education, completing a Master of Science in Clinical Education at the University of Edinburgh between 2018 and 2022, and became a Fellow of the Higher Education Academy in 2019. He is a member of the Academy of Medical Educators, and also sits on the executive council as the chair of the Membership Committee. He holds the Royal College of Pathologists' Medical Examiner qualification (RCPathME) and, in 2025, became a Chartered Manager of the Chartered Management Institute (CMgr MCMI). He also completed a distance-learning MBA Essentials course with the London School of Economics in 2018.

==Clinical practice and healthcare delivery==

Dr. Xiu joined Alwoodley Medical Centre in Leeds as a general practitioner in 2019 and continues to practise there.[1] He became a GP Trainer and Educational Supervisor in 2021 and supervises GP registrars at the practice.[1][5] Since 2023 he has served as Educational Lead for Central North Leeds Primary Care Network.

He has contributed to national primary care workforce and service development through several NHS and arm's-length body appointments. Since 2023 he has been a GP Clinical and Educational Supervisor for NHS England's Performance Advisory Group. Since 2023 he has served as a Medical Examiner for Leeds Teaching Hospitals, a statutory role involving independent scrutiny of deaths not referred to a coroner. Between 2022 and 2024 he was a Medical Assessor for the Vaccine Damage Payment Scheme. Since 2024 he has acted as a Medical Expert Witness for the General Medical Council, and since 2025 as a Specialist Advisor to the Care Quality Commission for primary medical services. In 2025 he was appointed an External Advisor in primary care to the Parliamentary and Health Service Ombudsman.

Dr. Xiu contributed to national health data policy as a board member of NHS Digital's Methodology Review Group from 2018 to 2019, a group concerned with the methodologies underpinning healthcare data collection and analysis.[5] He has also spoken publicly on digital health and patient control of health records, including a recorded discussion on blockchain and health information marking the NHS's seventieth anniversary in 2018.

==Medical education and publishing==

Dr. Xiu has been Series Editor of Elsevier's Crash Course series since 2016, a revision series covering approximately 25 titles across the basic and clinical sciences, and oversaw the sixth edition published in 2025.[5][8] Publisher listings credit him as author of Crash Course Pathology and as editor of titles including Crash Course Medical Ethics and Medical Law, Crash Course Anatomy and Physiology and Crash Course Cardiology. Elsevier has described the series as having sold more than one million copies internationally and as having been translated into more than eight languages.

Since 2019 he has been Elsevier's Editor-in-Chief for Global Medical Education on ClinicalKey Student International, and he has also served as ClinicalKey Student UK Assessment Editor-in-Chief. In 2026 he became Chair of the Elsevier AI Board for ClinicalKey Student UK, and he has spoken publicly on the use of artificial intelligence in health professions education, including an Elsevier Faculty Hub webinar and interview in June 2026 addressing assessment design, equitable educational outcomes and educator-student relationships. From 2020 he has also worked as Elsevier Health's OrderSet Medical Lead for Saudi Arabia. He discussed personalised learning and inclusive assessment design in an interview for the Raise the Line podcast.

His assessment and examining work includes serving as an OSCE examiner for Leeds University Medical School since 2019 and as a national senior examiner for the Prescribing Skills Assessment (PSA) since 2024. He became an Honorary Senior Lecturer and Education Supervisor at the University of Leeds in 2023. Since 2024 he has been a national e-learning author on the Medical Examiner programme for the Royal College of Pathologists. He is a member of the Faculty Advisory Board of The British Student Doctor Journal and of the editorial team of the Journal of the Academy of Medical Educators.

His educational work has received several awards. He was part of the team whose Kumar & Clark e-book (8th edition) won First Prize in the Digital and Online Resources category of the BMA Book Awards in 2013, and a further digital resource was Highly Commended in the same category. He received the Mark Brennan Prize from the Institute of Medical Ethics for innovations in teaching, learning and assessment in medical ethics and law, and the onExamination/BMJ prize for best national e-learning resource. Earlier in his career he received the London Deanery's Excellence in Leadership Award in 2012 and 2013, and was named Employee of the Month at North Middlesex University Hospital in January 2012.

==Pharmacy and non-medical prescriber education==

A distinct strand of Dr. Xiu's educational work concerns the training and supervision of pharmacists, an area that expanded in England following the introduction of the NHS Pharmacy First service and of independent prescribing within the pharmacy undergraduate curriculum. Since 2024 he has acted as a Pharmacist Designated Prescribing Practitioner (DPP) and Pharmacist Clinical Supervisor.[5] He has supervised more than 40 independent prescribing trainees across a range of NMP courses and offers clinical skills teaching, mock OSCEs and shadowing; these are self-described directory statements rather than independently audited figures.

He contributed to the development of the Centre for Pharmacy Postgraduate Education (CPPE) programme NHS Pharmacy First – Delivering a quality service. An article published by CPPE in November 2024 records that the programme "was developed with jobbing community pharmacy professionals delivering this service, and Dr Phil Xiu a GP", in a discussion concerning antibiotic expectation management and the use of RCGP TARGET resources. CPPE has also published educational content presented by him, spanning the whole of Pharmacy First clinical pathways, including material on what constitutes a good consultation record within the Pharmacy First programme and a clinical skills video demonstrating otoscopy and ear examination.

For Community Pharmacy West Yorkshire (CPWY), Dr. Xiu presented a seven-part Pharmacy First podcast series published in April 2026, covering clinical pathways for urinary tract infection, shingles, impetigo, infected insect bites and Lyme disease, otitis media, sore throat and sinusitis. In June 2026 CPWY published a guidance article attributed to him on independent prescribing for community pharmacists, addressing supervisor selection, clinical placements, consultation skills, portfolio preparation and the specific obstacles facing community-based trainees. He was subsequently named among the expert speakers at a CPWY independent prescribing webinar, the recording and FAQs of which were published in July 2026.

==Professional leadership and advisory roles==

Within the Royal College of General Practitioners, Dr. Xiu was appointed Faculty Vice Chair for Member Values in September 2026, having previously served as Honorary Treasurer of the Yorkshire Faculty from 2020. He has been a standing member of the College's Audit and Risk Committee since 2024, and Deputy Clinical Lead since 2026.[5] He has been a member of the Executive Council of the Academy of Medical Educators since 2022 and chairs its Membership Committee.

He joined the National Institute for Health and Care Excellence's Indicator Advisory Committee as a standing member in 2024, together with its Clinical Reference Group Committee; the Indicator Advisory Committee advises on the development of indicators used to measure quality in the NHS. Also since 2024 he has served as a board member of his Local Medical Committee and as a Director on the board of Healthwatch Leeds, the statutory local health and social care consumer champion.

==Research and publications==

Dr. Xiu's peer-reviewed publications are chiefly in cardiology and acute medicine, and include work on heart failure care in specialist and non-specialist services (Open Heart, 2015), post-procedural arterial hypertension after transcatheter aortic valve implantation (Journal of Heart Valve Disease, 2014), serum sodium as a prognostic marker in cardiac resynchronisation therapy (Indian Heart Journal, 2017), cryoablation for atrial fibrillation during concomitant cardiac surgery (Interactive CardioVascular and Thoracic Surgery, 2011), an electrocardiographic case report in Annals of Emergency Medicine (2014), and earlier neuroscience work on the nucleus of the solitary tract (Behavioural Brain Research, 2009). His book contributions include a chapter on stroke and cerebrovascular medicine in Drugs in Neurology (Oxford University Press, 2017), and editorial work on Kumar & Clark's Cases in Clinical Medicine (5th edition, 2025) and also as the associate editor of Medical Sciences (4th edition, 2025).
References

==References==

'''[https://www.alwoodleymedicalcentre.co.uk/about-us/meet-the-team/general-practitioner/dr-phil-xiu Alwoodley Medical Centre — "Dr Phil Xiu", GP profile]'''

'''[https://healthwatchleeds.co.uk/about-us/meet-the-board Healthwatch Leeds — "Meet the Board"]'''

'''[https://facultyhub.elsevier.com/en/ai-in-health-education-webinar Elsevier Faculty Hub — "AI in Health Education: Preparing Students for Real-World Clinical Readiness" (speaker biography, 18 June 2026)]'''

'''[https://www.youtube.com/watch?v=8aGMZKeg32E YouTube — "The NHS at 70 — Dr Philip Xiu". ]'''

'''[https://www.osmosis.org/podcast/tools-to-personalize-medical-education-phil-xiu-elsevier Osmosis / Elsevier — Raise the Line podcast, episode 369, "Tools to Personalize Medical Education'']'''

'''[https://www.bsdj.org.uk/philip-xiu The British Student Doctor Journal — "Philip Xiu", Faculty Advisory Board. ]'''

'''[https://www.rcgp.org.uk/membership/faculties/yorkshire RCGP — Yorkshire Faculty, Faculty Officers. ]'''

'''[https://www.nice.org.uk/get-involved/our-committees/nice-committee-meetings/indicator-advisory-committee/indicator-advisory-committee-members NICE — Indicator Advisory Committee members]'''

'''[https://scholar.google.com/citations?user=g92OaK8AAAAJ&hl=en Google Scholar — Philip Y. Xiu.]'''

'''[https://pubmed.ncbi.nlm.nih.gov/ PubMed — author search "Xiu PY".]'''

'''[https://uk.linkedin.com/in/philip-xiu LinkedIn — Philip Xiu]'''

Philip Xiu

2026-09-23T06:16:46Z

MrToy: new page created

{{Infobox person
| name = Philip Xiu [[File:Verified badge.png|20px]]
| image = Philip Xiu.png
| caption = Philip Xiu
| native_name = Philip Xiu
| birth_place = China
| birth_date = {{birth date and age|1987|3|27}}
| residence = China
| nationality = Chinese
| occupation = Doctor
| years_active = Present
}}
'''Philip Y. Xiu''' (born 1987) is a British general practitioner, medical educator and healthcare governance adviser based in Leeds, England. He practises as a GP at Alwoodley Medical Centre and holds an honorary senior lectureship at the University of Leeds. Alongside clinical practice he works in medical education publishing, serving as Elsevier's Series Editor for the Crash Course textbook series and as Editor-in-Chief for Global Medical Education on ClinicalKey Student International.[3][4] He also holds a number of regulatory and advisory appointments in the English health system, including Medical Examiner for Leeds Teaching Hospitals, Specialist Advisor to the Care Quality Commission, and External Advisor in primary care to the Parliamentary and Health Service Ombudsman. His work spans five overlapping areas: general practice, postgraduate and undergraduate medical education, pharmacy and non-medical prescriber education, clinical assessment and digital learning, and clinical governance.

==Early life and education==

Dr. Xiu was born in 1987. He studied medicine at Pembroke College, University of Cambridge, from 2005 to 2011, graduating MA (Cantab) and MB BChir. During his undergraduate years he held a series of academic awards, including a Foundation Award, a Foundation Scholarship, a Pembroke College Scholarship, a Pembroke College Prize, an Isaac Newton Bursary and the Foundress Prize for Medicine. His undergraduate and early research work was supported by the Peter Brook Research Prize, the Cambridge University De Novo Research Prize, a Wellcome Trust research grant and a Framlingham research grant.

From 2011 to 2015 he trained in London, first as an Academic Foundation Doctor and then as a Core Medical Trainee, obtaining membership of the Royal College of Physicians (MRCP). He subsequently moved into general practice training, entering GP specialty training in 2016 and qualifying as a general practitioner in 2019 with membership of the Royal College of General Practitioners (MRCGP). He undertook further academic study in education, completing a Master of Science in Clinical Education at the University of Edinburgh between 2018 and 2022, and became a Fellow of the Higher Education Academy in 2019. He is a member of the Academy of Medical Educators, and also sits on the executive council as the chair of the Membership Committee. He holds the Royal College of Pathologists' Medical Examiner qualification (RCPathME) and, in 2025, became a Chartered Manager of the Chartered Management Institute (CMgr MCMI). He also completed a distance-learning MBA Essentials course with the London School of Economics in 2018.

Clinical practice and healthcare delivery

Dr. Xiu joined Alwoodley Medical Centre in Leeds as a general practitioner in 2019 and continues to practise there.[1] He became a GP Trainer and Educational Supervisor in 2021 and supervises GP registrars at the practice.[1][5] Since 2023 he has served as Educational Lead for Central North Leeds Primary Care Network.

He has contributed to national primary care workforce and service development through several NHS and arm's-length body appointments. Since 2023 he has been a GP Clinical and Educational Supervisor for NHS England's Performance Advisory Group. Since 2023 he has served as a Medical Examiner for Leeds Teaching Hospitals, a statutory role involving independent scrutiny of deaths not referred to a coroner. Between 2022 and 2024 he was a Medical Assessor for the Vaccine Damage Payment Scheme. Since 2024 he has acted as a Medical Expert Witness for the General Medical Council, and since 2025 as a Specialist Advisor to the Care Quality Commission for primary medical services. In 2025 he was appointed an External Advisor in primary care to the Parliamentary and Health Service Ombudsman.

Dr. Xiu contributed to national health data policy as a board member of NHS Digital's Methodology Review Group from 2018 to 2019, a group concerned with the methodologies underpinning healthcare data collection and analysis.[5] He has also spoken publicly on digital health and patient control of health records, including a recorded discussion on blockchain and health information marking the NHS's seventieth anniversary in 2018.

Medical education and publishing

Dr. Xiu has been Series Editor of Elsevier's Crash Course series since 2016, a revision series covering approximately 25 titles across the basic and clinical sciences, and oversaw the sixth edition published in 2025.[5][8] Publisher listings credit him as author of Crash Course Pathology and as editor of titles including Crash Course Medical Ethics and Medical Law, Crash Course Anatomy and Physiology and Crash Course Cardiology. Elsevier has described the series as having sold more than one million copies internationally and as having been translated into more than eight languages.

Since 2019 he has been Elsevier's Editor-in-Chief for Global Medical Education on ClinicalKey Student International, and he has also served as ClinicalKey Student UK Assessment Editor-in-Chief. In 2026 he became Chair of the Elsevier AI Board for ClinicalKey Student UK, and he has spoken publicly on the use of artificial intelligence in health professions education, including an Elsevier Faculty Hub webinar and interview in June 2026 addressing assessment design, equitable educational outcomes and educator-student relationships. From 2020 he has also worked as Elsevier Health's OrderSet Medical Lead for Saudi Arabia. He discussed personalised learning and inclusive assessment design in an interview for the Raise the Line podcast.

His assessment and examining work includes serving as an OSCE examiner for Leeds University Medical School since 2019 and as a national senior examiner for the Prescribing Skills Assessment (PSA) since 2024. He became an Honorary Senior Lecturer and Education Supervisor at the University of Leeds in 2023. Since 2024 he has been a national e-learning author on the Medical Examiner programme for the Royal College of Pathologists. He is a member of the Faculty Advisory Board of The British Student Doctor Journal and of the editorial team of the Journal of the Academy of Medical Educators.

His educational work has received several awards. He was part of the team whose Kumar & Clark e-book (8th edition) won First Prize in the Digital and Online Resources category of the BMA Book Awards in 2013, and a further digital resource was Highly Commended in the same category. He received the Mark Brennan Prize from the Institute of Medical Ethics for innovations in teaching, learning and assessment in medical ethics and law, and the onExamination/BMJ prize for best national e-learning resource. Earlier in his career he received the London Deanery's Excellence in Leadership Award in 2012 and 2013, and was named Employee of the Month at North Middlesex University Hospital in January 2012.

Pharmacy and non-medical prescriber education

A distinct strand of Dr. Xiu's educational work concerns the training and supervision of pharmacists, an area that expanded in England following the introduction of the NHS Pharmacy First service and of independent prescribing within the pharmacy undergraduate curriculum. Since 2024 he has acted as a Pharmacist Designated Prescribing Practitioner (DPP) and Pharmacist Clinical Supervisor.[5] He has supervised more than 40 independent prescribing trainees across a range of NMP courses and offers clinical skills teaching, mock OSCEs and shadowing; these are self-described directory statements rather than independently audited figures.

He contributed to the development of the Centre for Pharmacy Postgraduate Education (CPPE) programme NHS Pharmacy First – Delivering a quality service. An article published by CPPE in November 2024 records that the programme "was developed with jobbing community pharmacy professionals delivering this service, and Dr Phil Xiu a GP", in a discussion concerning antibiotic expectation management and the use of RCGP TARGET resources. CPPE has also published educational content presented by him, spanning the whole of Pharmacy First clinical pathways, including material on what constitutes a good consultation record within the Pharmacy First programme and a clinical skills video demonstrating otoscopy and ear examination.

For Community Pharmacy West Yorkshire (CPWY), Dr. Xiu presented a seven-part Pharmacy First podcast series published in April 2026, covering clinical pathways for urinary tract infection, shingles, impetigo, infected insect bites and Lyme disease, otitis media, sore throat and sinusitis. In June 2026 CPWY published a guidance article attributed to him on independent prescribing for community pharmacists, addressing supervisor selection, clinical placements, consultation skills, portfolio preparation and the specific obstacles facing community-based trainees. He was subsequently named among the expert speakers at a CPWY independent prescribing webinar, the recording and FAQs of which were published in July 2026.

Professional leadership and advisory roles

Within the Royal College of General Practitioners, Dr. Xiu was appointed Faculty Vice Chair for Member Values in September 2026, having previously served as Honorary Treasurer of the Yorkshire Faculty from 2020. He has been a standing member of the College's Audit and Risk Committee since 2024, and Deputy Clinical Lead since 2026.[5] He has been a member of the Executive Council of the Academy of Medical Educators since 2022 and chairs its Membership Committee.

He joined the National Institute for Health and Care Excellence's Indicator Advisory Committee as a standing member in 2024, together with its Clinical Reference Group Committee; the Indicator Advisory Committee advises on the development of indicators used to measure quality in the NHS. Also since 2024 he has served as a board member of his Local Medical Committee and as a Director on the board of Healthwatch Leeds, the statutory local health and social care consumer champion.

Research and publications

Dr. Xiu's peer-reviewed publications are chiefly in cardiology and acute medicine, and include work on heart failure care in specialist and non-specialist services (Open Heart, 2015), post-procedural arterial hypertension after transcatheter aortic valve implantation (Journal of Heart Valve Disease, 2014), serum sodium as a prognostic marker in cardiac resynchronisation therapy (Indian Heart Journal, 2017), cryoablation for atrial fibrillation during concomitant cardiac surgery (Interactive CardioVascular and Thoracic Surgery, 2011), an electrocardiographic case report in Annals of Emergency Medicine (2014), and earlier neuroscience work on the nucleus of the solitary tract (Behavioural Brain Research, 2009). His book contributions include a chapter on stroke and cerebrovascular medicine in Drugs in Neurology (Oxford University Press, 2017), and editorial work on Kumar & Clark's Cases in Clinical Medicine (5th edition, 2025) and also as the associate editor of Medical Sciences (4th edition, 2025).
References

==References==

'''[https://www.alwoodleymedicalcentre.co.uk/about-us/meet-the-team/general-practitioner/dr-phil-xiu Alwoodley Medical Centre — "Dr Phil Xiu", GP profile]'''

'''[https://healthwatchleeds.co.uk/about-us/meet-the-board Healthwatch Leeds — "Meet the Board"]'''

'''[https://facultyhub.elsevier.com/en/ai-in-health-education-webinar Elsevier Faculty Hub — "AI in Health Education: Preparing Students for Real-World Clinical Readiness" (speaker biography, 18 June 2026)]'''

'''[https://www.youtube.com/watch?v=8aGMZKeg32E YouTube — "The NHS at 70 — Dr Philip Xiu". ]'''

'''[https://www.osmosis.org/podcast/tools-to-personalize-medical-education-phil-xiu-elsevier Osmosis / Elsevier — Raise the Line podcast, episode 369, "Tools to Personalize Medical Education'']'''

'''[https://www.bsdj.org.uk/philip-xiu The British Student Doctor Journal — "Philip Xiu", Faculty Advisory Board. ]'''

'''[https://www.rcgp.org.uk/membership/faculties/yorkshire RCGP — Yorkshire Faculty, Faculty Officers. ]'''

'''[https://www.nice.org.uk/get-involved/our-committees/nice-committee-meetings/indicator-advisory-committee/indicator-advisory-committee-members NICE — Indicator Advisory Committee members]'''

'''[https://scholar.google.com/citations?user=g92OaK8AAAAJ&hl=en Google Scholar — Philip Y. Xiu.]'''

'''[https://pubmed.ncbi.nlm.nih.gov/ PubMed — author search "Xiu PY".]'''

'''[https://uk.linkedin.com/in/philip-xiu LinkedIn — Philip Xiu]'''

File:Philip Xiu.png

2026-09-23T06:16:18Z

MrToy: Philip Xiu

== Summary ==
Philip Xiu

File:Americans 4 Equality training.jpg

2026-08-31T02:31:16Z

MrToy:

File:Omer Qureshi speaking.jpg

2026-08-31T02:30:44Z

MrToy:

File:Omer Qureshi Forbes Councils.jpg

2026-08-31T02:30:15Z

MrToy:

File:Americans 4 Equality interns.jpg

2026-08-31T02:29:04Z

MrToy:

File:Americans 4 Equality logo.png

2026-08-31T02:28:41Z

MrToy:

File:Omer Qureshi partner workshop.jpg

2026-08-31T02:28:16Z

MrToy:

File:Omer Qureshi keynote.jpg

2026-08-31T02:27:53Z

MrToy:

File:Omer Qureshi boardroom.jpg

2026-08-31T02:27:21Z

MrToy:

File:Omer Qureshi whiteboard summary.jpg

2026-08-31T02:26:33Z

MrToy:

Omer Qureshi

2026-08-31T02:25:58Z

MrToy: Created page with "{{Infobox person | name = Omer Qureshi | image = Omer_Qureshi_headshot.jpg | image_size = 250px | caption = Omer Qureshi | home_town = Bellevue, Washington, U.S. | residence = Bellevue, Washington, U.S. | nationality = American | citizenship = United States | alma_mater = University of California, Berkeley Wittenberg University | occupation = Technology executive, nonprofit co-founder | years_active = 2001–prese..."

{{Infobox person
| name = Omer Qureshi
| image = Omer_Qureshi_headshot.jpg
| image_size = 250px
| caption = Omer Qureshi
| home_town = [[Bellevue, Washington]], U.S.
| residence = [[Bellevue, Washington]], U.S.
| nationality = American
| citizenship = United States
| alma_mater = University of California, Berkeley Wittenberg University
| occupation = Technology executive, nonprofit co-founder
| years_active = 2001–present
| employer = Kovrr Americans 4 Equality Optimus
| title = SVP, Cybersecurity GTM & Partner Ecosystem, Kovrr CEO & Co-Founder, Americans 4 Equality
| known_for = Partner ecosystem architecture, hyperscaler co-sell, cybersecurity go-to-market
| awards = Triple Partner of the Year, 2023 (Microsoft, AWS, Google Cloud — client organisations)
| website = {{URL|https://omerpro.com/}}
}}

'''Omer Qureshi''' is an American technology executive and nonprofit co-founder based in [[Bellevue, Washington]]. Over two decades he has built partner ecosystems for Microsoft, VMware, Avaya, Bank of America and Noventiq, accounting for more than $1.5 billion in partner-influenced annual recurring revenue at 30 per cent year-over-year growth, over $500 million in negotiated mergers, acquisitions and strategic deal value, and partner programmes activated across more than 38 countries.<ref name="omerpro" /><ref name="linkedin" /> He specialises in partner ecosystem architecture, hyperscaler co-sell, cybersecurity go-to-market, and mergers and acquisitions integration. He is Senior Vice President of Cybersecurity GTM and Partner Ecosystem at Kovrr, and co-founder and chief executive officer of Americans 4 Equality, a 501(c)(3) nonprofit providing free technology training across Washington and Oregon.<ref name="seattlemedium" /><ref name="omerpro" />

[[File:Omer_Qureshi_whiteboard_summary.jpg|thumb|center|600px|Overview of Qureshi's work: partner ecosystem architecture, hyperscaler and cybersecurity go-to-market, the partner ecosystem he operates across, and Americans 4 Equality]]

== Early career ==

Qureshi began his career in enterprise technology at Bank of America, where he served as Vice President, Data Centers and Trading Operations from 2001 to 2006, working on infrastructure and systems for financial services.<ref name="linkedin" />

== Technology career ==

=== Microsoft, VMware and Avaya ===

Qureshi joined Microsoft in 2006 as Managing Director, Enterprise Sales, a role he held until 2012, leading enterprise sales for data centre, cloud and application solutions across North America and Europe. He built a business exceeding $100 million in annual recurring revenue, closed more than 200 cloud customer wins, and was named Manager of the Year.<ref name="linkedin" />

He moved to VMware in 2012 as Regional Sales Director, Enterprise and Cloud, during the period in which server virtualisation was being adopted widely across enterprise data centres.<ref name="linkedin" />

He returned to Microsoft in 2013 as Director, Partner Ecosystems and Global Alliances, a role he held until 2017, building alliance programmes across global systems integrators, telecommunications providers, managed service providers and resellers. He managed an $11.7 million profit-and-loss line and a team of 21 alliance professionals across 24 countries, generating more than $100 million in partner-sourced annual recurring revenue, and was recognised in the Microsoft Gold Club in 2014.<ref name="linkedin" />

From 2017 to 2021 he served as General Manager, Cloud Sales and Partnerships at Avaya, focused on cloud and artificial intelligence within the company's cloud solutions business, leading a 56-person organisation and a portfolio exceeding $156 million in annual recurring revenue.<ref name="linkedin" />

[[File:Omer_Qureshi_boardroom.jpg|thumb|left|280px|Qureshi in a corporate boardroom]]

=== Noventiq ===

In 2021 Softline, later renamed Noventiq, appointed Qureshi Vice President of Global Strategic Partnerships and Alliances, a role he held until 2024.<ref name="medianews4u" /> His remit centred on the Microsoft partnership and on bringing Microsoft cloud and cybersecurity products into the company's operating regions.<ref name="medianews4u" />

At Noventiq he led a global partner organisation of 44 alliance professionals and a business representing more than $1.5 billion in partner-influenced annual recurring revenue across 38 countries, growing 30 per cent year over year. He directed a $17 million three-year Microsoft alliance investment that returned tenfold within 18 months, secured $5 million in AWS strategic collaboration funding, and led go-to-market integration across eight acquisitions totalling more than $500 million in deal value.<ref name="linkedin" /><ref name="omerpro" />

=== Triple Partner of the Year ===

In the same year, partner organisations operating under strategies Qureshi designed and led were named Partner of the Year by all three major hyperscalers — a combination rarely achieved across Microsoft, Amazon Web Services and Google Cloud simultaneously. Noventiq was named Microsoft Country Partner of the Year in seven countries for 2024<ref name="noventiqms" /> and was recognised by Amazon Web Services.<ref name="noventiqaws" /> A separate client engagement through his advisory practice earned the Google Cloud recognition. The awards were conferred on the organisations; Qureshi's role was as the architect of the partner strategies behind them.<ref name="techbullion" />

[[File:Omer_Qureshi_keynote.jpg|thumb|right|300px|Qureshi delivering a keynote on partner ecosystems]]

=== Cybersecurity and advisory work ===

Qureshi holds a senior partnerships role at Kovrr, which works in cyber risk quantification — translating security posture into financial exposure that boards, insurers and finance functions can act on.<ref name="kovrr" /> He advises InfoSec Global on cryptographic agility and post-quantum readiness, and has written on non-human identity security and the credentialing of autonomous AI agents.<ref name="omerpro" />

[[File:Omer_Qureshi_partner_workshop.jpg|thumb|right|300px|Cross-functional partner workshop on co-sell and co-marketing]]

Through Optimus, the advisory practice he founded in 2016, he works on hyperscaler partnerships, channel strategy, cybersecurity go-to-market and post-acquisition integration, including fractional chief partner officer engagements. He has served as a trusted advisor to technology companies across cloud, cybersecurity and managed services.<ref name="optimus" /><ref name="techbullion" />

== Americans 4 Equality ==

[[File:Americans_4_Equality_logo.png|thumb|left|120px|Americans 4 Equality]]

Qureshi is co-founder and chief executive officer of Americans 4 Equality, also known as A4E and subtitled The MLK Gandhi Empowerment Initiative. The organisation is a 501(c)(3) nonprofit headquartered in Bellevue, Washington, serving Washington and Oregon, and has held 501(c)(3) status since 2020. Its flagship programme launched in October 2024. Its founding member and chairperson is Eddie Rye Jr.<ref name="seattlemedium" /><ref name="guidestar" />

[[File:Americans_4_Equality_interns.jpg|thumb|right|300px|Qureshi with an Americans 4 Equality intern cohort]]

All programmes are provided at no cost. Eligibility requires participants to be 18 or older, a Washington or Oregon resident, authorised to work in the United States, able to read and write English, and to have basic computer skills. No diploma or prior experience is required. The entry-level Warp 1 programme admits participants from age 13 with parental consent.<ref name="omerpro" />

The flagship course runs 120 hours, covering cloud computing, cybersecurity, programming, generative artificial intelligence, data analytics and corporate readiness. Shorter introductory courses run in partnership with Community Passageways and Africatown.<ref name="seattlemedium" />

As of June 2026, the organisation reports having served more than 1,139 people, with an 88 per cent completion rate and a 60 per cent job placement rate. It has placed more than 40 interns and holds more than 15 partnerships.<ref name="omerpro" />

In the federal government funding package, Americans 4 Equality received a $2.23 million appropriation for the MLK-Gandhi Empowerment Initiative, secured through Representative Adam Smith.<ref name="housefunding" /> Fifty-five per cent of participants are women, and the organisation has been recognised by Senator Patty Murray for advancing equitable workforce development.<ref name="omerpro" />

[[File:Americans_4_Equality_training.jpg|thumb|left|300px|An Americans 4 Equality training session]]

Qureshi presented to the Seattle City Council on 16 September 2025.<ref name="seattlecouncil" />

== Writing and speaking ==

[[File:Omer_Qureshi_Forbes_Councils.jpg|thumb|right|220px|Forbes Councils membership]]

Qureshi is a member of the Forbes Business Council and the Forbes Nonprofit Council, where he has published articles on artificial-intelligence-first operations, skills-based hiring, and adopting AI in nonprofit organisations.<ref name="forbes" /> He also publishes long-form essays on partner ecosystems and channel strategy.<ref name="substack" />

[[File:Omer_Qureshi_speaking.jpg|thumb|left|300px|Speaking on partner ecosystems and AI go-to-market]]

He has spoken on partner ecosystems, hyperscaler co-sell, cybersecurity go-to-market and workforce development, and has appeared before local government bodies in the Puget Sound region.<ref name="seattlecouncil" />

== Recognition ==

* Triple Partner of the Year, 2023 — client organisations recognised by Microsoft, Amazon Web Services and Google Cloud in the same year<ref name="noventiqms" /><ref name="noventiqaws" />
* Microsoft Country Partner of the Year, 2024 — seven countries, Noventiq<ref name="noventiqms" />
* Microsoft Gold Club, 2014<ref name="linkedin" />
* Manager of the Year, Microsoft<ref name="linkedin" />
* Member, Forbes Business Council and Forbes Nonprofit Council<ref name="forbes" />

== Education ==

Qureshi studied business and managerial economics at the University of California, Berkeley, and holds a bachelor's degree in management information systems from Wittenberg University.<ref name="linkedin" />

== See also ==

* Partner ecosystem
* Cyber risk quantification
* Post-quantum cryptography

== References ==

<references>
<ref name="omerpro">[https://omerpro.com/ Omer Qureshi — official website]</ref>
<ref name="seattlemedium">Allen, Aaron. [https://seattlemedium.com/mlk-gandhi-empowerment-initiative/ "MLK Gandhi Empowerment Initiative Brings Tech Careers Within Reach"], ''The Seattle Medium'', 30 May 2025.</ref>
<ref name="housefunding">[https://adamsmith.house.gov/news/press-releases/house-sends-government-funding-package-president-bidens-desk-be-signed-law "House Sends Government Funding Package to President's Desk to be Signed into Law"], U.S. Representative Adam Smith. Lists $2.23 million for Americans for Equality, MLK-Gandhi Empowerment Initiative.</ref>
<ref name="seattlecouncil">[https://video.seattle.gov/media/council/council_091625_2022575.mp4 Seattle City Council session, 16 September 2025], City of Seattle video archive.</ref>
<ref name="medianews4u">[https://www.medianews4u.com/softline-appoints-omer-qureshi-as-vp-of-strategic-alliances/ "Softline appoints Omer Qureshi as VP of Strategic Alliances"], ''MediaNews4U'', 19 October 2021.</ref>
<ref name="noventiqms">[https://noventiq.com/news/noventiq-recognized-as-winner-of-2024-microsoft-country-partner-of-the-year-in-7-countries "Noventiq recognized as winner of 2024 Microsoft Country Partner of the Year in 7 countries"], Noventiq.</ref>
<ref name="noventiqaws">[https://aws.noventiq.com/aws-noventiq-awards AWS Noventiq awards], Noventiq.</ref>
<ref name="guidestar">[https://www.guidestar.org/profile/85-2365649 Americans 4 Equality — Candid/GuideStar profile], EIN 85-2365649.</ref>
<ref name="forbes">[https://councils.forbes.com/profile/Omer-Qureshi-CEO-Co-Founder-Americans-4-Equality/4be3a949-2eab-49e8-b443-355ff604df9b Omer Qureshi — Forbes Councils profile].</ref>
<ref name="substack">[https://substack.com/@omerpro Omer Qureshi on Substack].</ref>
<ref name="linkedin">[https://www.linkedin.com/in/omerq/ Omer Qureshi — LinkedIn profile].</ref>
<ref name="kovrr">[https://kovrr.com/ Kovrr] — cyber risk quantification.</ref>
<ref name="optimus">[https://optimus.llc/ Optimus] — executive advisory practice.</ref>
<ref name="techbullion">[https://techbullion.com/omer-qureshi-the-executive-who-builds-how-enterprise-technology-reaches-the-world/ "Omer Qureshi: The Executive Who Builds How Enterprise Technology Reaches the World"], ''TechBullion'', 30 August 2026.</ref>
</references>

== External links ==

* [https://omerpro.com/ Official website]
* [https://www.linkedin.com/in/omerq/ LinkedIn]
* [https://x.com/omerpro X]
* [https://substack.com/@omerpro Substack]
* [https://councils.forbes.com/profile/Omer-Qureshi-CEO-Co-Founder-Americans-4-Equality/4be3a949-2eab-49e8-b443-355ff604df9b Forbes Councils profile]
* [https://americans4equality.org/ Americans 4 Equality]
* [https://optimus.llc/ Optimus]

[[Category:Living people]]
[[Category:American technology executives]]
[[Category:American nonprofit chief executives]]
[[Category:People from Bellevue, Washington]]
[[Category:University of California, Berkeley alumni]]
[[Category:Wittenberg University alumni]]

File:Omer Qureshi headshot.jpg

2026-08-31T02:25:24Z

MrToy: Omer Qureshi

== Summary ==
Omer Qureshi

Evan Era

2026-08-30T02:17:41Z

MrToy:

{{Infobox person
| name = Evan Era {{verified}}
| image = Evan Era.jpeg
| caption = Evan Era
| native_name = Evan Era
| birth_place = Louisville, Kentucky, United States Of America
| birth_date = {{birth date and age|1986|7|25}}
| residence = Louisville, Kentucky, United States Of America
| nationality = American
| occupation = Actor
| years_active = Present
| home_town = Louisville
| website = https://www.famousbirthdays.com/people/evan-era.html
}}

'''Evan Era''' is an American magician, producer, actor, screenwriter, entrepreneur, and digital creator from Louisville, Kentucky. He is best known as the creator of How To Magic and EvanEraTV, where he built an international audience through magic, comedy, entertainment, and original digital programming.

Era began his career as a performing magician before expanding into digital media, launching How To Magic on YouTube and developing it into a widely recognized magic and entertainment brand. His work has since grown to encompass short-form and long-form digital content, television screenwriting and production, filmmaking, acting, visual storytelling, and the development of original entertainment concepts.

With an audience of more than 10 million followers across social platforms and billions of video views, Era has built a career at the intersection of traditional entertainment and modern creator-led media. He is the founder of Era Media Group, an entertainment and production company developing original content, intellectual property, digital programming, and projects for television, film, and emerging media platforms.

==References==

'''[https://www.instagram.com/evanrosenman Instagram]'''

'''[https://www.facebook.com/EvanEraTV/ Facebook]'''

'''[https://www.youtube.com/evaneratv Youtube]'''

Jami McGuairt-Salazar

2026-08-29T04:59:28Z

MrToy: update

{{Infobox person
| name = Jami McGuairt-Salazar {{verified}}
| image = Jami McGuairt-Salazar.jpg
| caption = Jami McGuairt-Salazar
| native_name = Jami McGuairt-Salazar
| birth_place = Fort Stockton, Texas, United States Of America
| birth_date = August 9, 1990 (age 36 years)
| residence = Fort Stockton, Texas, United States Of America
| nationality = American
| occupation = Influencer
| years_active = Present
| home_town = Fort Stockton
}}

Jami McGuairt-Salazar is a Texas-born American socialite, influencer, philanthropist, and member of the Texas-based family office Two Texas Presidents. Known for her involvement in philanthropic, social, and civic initiatives, she has established a presence across social, political, and nonprofit communities. She is married to Dallas C. Salazar, an American industrialist and commodities investor.

==References==

'''[https://www.instagram.com/xoxotheduchessxoxo Instagram]'''

Dallas Salazar

2026-08-29T04:58:23Z

MrToy:

{{Infobox person
| name = Dallas Salazar {{verified}}
| image = Dallas Salazar.png
| caption = Dallas Salazar
| native_name = Dallas Salazar
| birth_place = San Bernardino, California, United States Of America
| birth_date = August 21, 1987 (age 38 years)
| residence = San Bernardino, California, United States Of America
| nationality = American
| occupation = Investor
| years_active = Present
| home_town = San Bernardino
| website = https://twitter.com/FracTechWildcat
}}

'''Dallas Salazar''' is the managing member of an Austin-based family office, Two Texas Presidents. '''Mr. Salazar's''' family office primarily acts as venture capital or private credit for natural resource extraction companies. Mr. Salazar has previously invested in a portfolio of energy and commodity startups, including startups extracting oil, natural gas, helium, and carbon dioxide, as well as engaged in the business of large scale carbon sequestration. Mr. Salazar has recently had large, multi-billion dollar exits in Comstock Resources, Eclipse Resources, Southwestern Energy, as well as numerous privately held natural resource and commodity extraction ventures.

==References==

'''[https://twitter.com/FracTechWildcat Twitter]'''

Dallas Salazar

2026-08-29T04:12:42Z

MrToy:

Evan Era

2026-08-29T03:51:49Z

MrToy: new page created

{{Infobox person
| name = Evan Era {{verified}}
| image = Evan Era.jpeg
| caption = Evan Era
| native_name = Evan Era
| birth_place = Louisville, Kentucky, United States Of America
| birth_date = {{birth date and age|1986|7|25}}
| residence = Louisville, Kentucky, United States Of America
| nationality = American
| occupation = Musical artist
| years_active = Present
| home_town = Louisville
| website = https://www.famousbirthdays.com/people/evan-era.html
}}

'''Evan Era''' is an American magician, producer, actor, screenwriter, entrepreneur, and digital creator from Louisville, Kentucky. He is best known as the creator of How To Magic and EvanEraTV, where he built an international audience through magic, comedy, entertainment, and original digital programming.

Era began his career as a performing magician before expanding into digital media, launching How To Magic on YouTube and developing it into a widely recognized magic and entertainment brand. His work has since grown to encompass short-form and long-form digital content, television screenwriting and production, filmmaking, acting, visual storytelling, and the development of original entertainment concepts.

With an audience of more than 10 million followers across social platforms and billions of video views, Era has built a career at the intersection of traditional entertainment and modern creator-led media. He is the founder of Era Media Group, an entertainment and production company developing original content, intellectual property, digital programming, and projects for television, film, and emerging media platforms.

==References==

'''[https://www.instagram.com/evanrosenman Instagram]'''

'''[https://www.facebook.com/EvanEraTV/ Facebook]'''

'''[https://www.youtube.com/evaneratv Youtube]'''

File:Evan Era.jpeg

2026-08-29T03:51:17Z

MrToy: Evan Era

== Summary ==
Evan Era

James Demuth

2026-08-29T03:46:41Z

MrToy:

{{Infobox person
| name = James Demuth [[File:Verified badge.png|20px]]
| image = James Demuth.jpg
| caption = James Demuth
| native_name = James Demuth
| birth_place = Kirkland, Washington, D.C, United States Of America
| birth_date = June 29, 1986 (age 39 years)
| residence = Kirkland, Washington, D.C
| nationality = American
| occupation = Entrepreneur
| years_active = Present
| home_town = Kirkland, Washington, D.C
}}

'''James DeMuth''' is the '''CEO and co-founder of Seurat Technologies and Entrepreneur''', a metal 3D printing company focused on reshoring and scaling advanced manufacturing in the United States. With a background in mechanical engineering and over 140 patents to his name, James began his career as a researcher at Lawrence Livermore National Laboratory, where he co-invented Seurat’s core technology. He now leads Seurat’s mission to replace traditional casting and machining with flexible, high-speed production that supports innovation, supply chain resilience, and national security.

==References==

'''[https://g.co/kgs/kwB2PSA Google Panel]'''

Immix Biopharma

2026-08-18T07:14:33Z

MrToy: Created page with "{{Infobox company | name = Immix Biopharma, Inc. | trading_name = ImmixBio | logo = Immix Biopharma.jpeg | industry = Biotechnology and biopharmaceuticals | founded = 2012 | founder = Ilya Rachman | headquarters = Los Angeles, California, United States | address = 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA 90064 | traded_as = {{NASDAQ|IMMX}} | key_people = Ilya Rachman (Founder, Chairman and CEO) Gabriel Morris (President and CFO) Michae..."

{{Infobox company
| name = Immix Biopharma, Inc.
| trading_name = ImmixBio
| logo = Immix Biopharma.jpeg
| industry = Biotechnology and biopharmaceuticals
| founded = 2012
| founder = [[Ilya Rachman]]
| headquarters = Los Angeles, California, United States
| address = 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA 90064
| traded_as = {{NASDAQ|IMMX}}
| key_people = [[Ilya Rachman]] (Founder, Chairman and CEO) [[Gabriel Morris]] (President and CFO) [[Michael Grabow]] (Chief Commercial Officer)
| products = NXC-201
| website = {{URL|https://immixbio.com}}
| employees = Approximately 60
}}

'''Immix Biopharma, Inc.''', also known as '''ImmixBio''', is an American clinical-stage biopharmaceutical company focused on developing cell therapies and other immune-based treatments for rare diseases.<ref name="ref1">https://www.edisongroup.com/equity/immix-biopharma/</ref> The company was founded in 2012 by physician-scientist [[Ilya Rachman]], MD PhD and is headquartered in Los Angeles, California.<ref name="ref2">https://www.sec.gov/Archives/edgar/data/1873835/000149315221022940/forms-1.htm</ref> Its common stock is publicly traded on the Nasdaq Capital Market under the ticker symbol [https://www.nasdaq.com/market-activity/stocks/immx IMMX].

Immix Biopharma's principal clinical program is NXC-201, a BCMA-targeted chimeric antigen receptor T-cell therapy being investigated for relapsed or refractory light-chain amyloidosis, commonly known as AL amyloidosis.<ref name="ref3">https://consultqd.clevelandclinic.org/first-ever-us-trial-of-car-t-cell-therapy-for-relapsedrefractory-al-amyloidosis</ref> The company's broader mission is to harness the immune system through innovative cell therapies and other modalities to develop widely accessible treatments for autoimmune diseases and other serious indications.

==History==

===Founding===

Immix Biopharma was founded in 2012 by [[Ilya Rachman]], MD PhD, a physician-scientist with experience in clinical medicine, neuroendocrinology, experimental oncology and pharmaceutical clinical research.<ref name="ref4">https://scholar.google.com/citations?user=9NaulC8AAAAJ&hl=en</ref>

Rachman became interested in therapeutic development after treating thousands of patients and repeatedly encountering situations in which no further treatment options were available.<ref name="ref5">https://www.youtube.com/watch?v=_b-4UcAoH9c</ref> He later pursued business training at the University of California, Los Angeles, and founded Immix Biopharma with the objective of translating scientific research into new therapeutic options for patients.

During its early years, the company developed and tested an initial drug candidate, raised capital from private investors and later completed an initial public offering. Its early research was primarily associated with oncology and the application of academic discoveries to potential cancer treatments.

===Expansion into cell therapy===

Following its public listing, Immix Biopharma began evaluating whether advanced cell therapies traditionally associated with cancer treatment could be applied to diseases outside conventional oncology.

In 2022, the company initiated a systematic search for cell-therapy assets and licensed global intellectual-property rights relating to NXC-201 from Hadassah in Israel. The program subsequently became the company's principal clinical-stage asset.

This strategic shift moved Immix Biopharma toward the development of CAR-T cell therapy for AL amyloidosis, a rare systemic disease in which abnormal plasma cells produce toxic light chains that can accumulate in organs including the heart, kidneys and liver.

==NXC-201==

'''NXC-201''' is an investigational, BCMA-targeted chimeric antigen receptor T-cell therapy being developed by Immix Biopharma for relapsed or refractory AL amyloidosis.<ref name="ref6">https://www.mskcc.org/news/car-cell-therapy-for-light-chain-al-amyloidosis-achieves-strong-results</ref>

NXC-201 is described as a sterically optimised CAR-T therapy incorporating a proprietary CD3ζ signaling domain, CD8 hinge and binder-based "digital filter."<ref name="ref7">https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7508</ref> The design is intended to reduce non-specific activation while enabling engineered T cells to identify and eliminate the plasma cells responsible for producing toxic light chains.

NXC-201 targets B-cell maturation antigen, or BCMA, which is expressed on plasma cells. The programme represents Immix Biopharma's effort to extend the potential application of BCMA-directed CAR-T therapy beyond conventional oncology into AL amyloidosis.

NXC-201 remains investigational and has not been approved for commercial use.

==AL amyloidosis==

AL amyloidosis is a rare disorder caused by abnormal plasma cells that produce misfolded immunoglobulin light chains. These proteins can accumulate in organs and tissues, potentially leading to progressive damage to the heart, kidneys, liver and other organs.

Immix Biopharma's development strategy is based on targeting the abnormal plasma cells responsible for producing the disease-causing light chains rather than treating only the resulting organ damage.

The disease has historically had limited treatment options specifically approved for AL amyloidosis, creating a need for new therapeutic approaches.

==Clinical development==

===NEXICART-1===

NXC-201 was initially evaluated outside the United States in the NEXICART-1 clinical study.

The NEXICART-1 program reported a 75% complete response rate in the relevant AL amyloidosis patient population.<ref name="ref8">https://ashpublications.org/blood/article/146/Supplement%201/696/554962/First-20-patient-safety-and-efficacy-data-from</ref> Clinical findings associated with NXC-201 were subsequently discussed in medical literature and presented through scientific and professional forums.<ref name="ref9">https://ascopost.com/news/june-2025/early-results-for-car-t-cell-therapy-for-relapsed-or-refractory-al-amyloidosis/</ref>

===NEXICART-2===

Immix Biopharma is evaluating NXC-201 in the United States through NEXICART-2, a multicentre study for patients with relapsed or refractory AL amyloidosis.<ref name="ref10">https://www.vjhemonc.com/video/ofthc2v8em0-initial-results-from-the-nexicart-2-trial-of-bcma-directed-car-t-nxc-201-in-rr-al-amyloidosis/</ref>

The trial is registered as NCT06097832 and has a potentially registrational design. Its development strategy may support a future regulatory submission if the required clinical and regulatory standards are met.

Initial results from the program have been discussed through oncology and hematology publications, scientific-video platforms and professional meetings, including materials associated with the American Society of Clinical Oncology and the American Society of Hematology.

==Regulatory designations==

NXC-201 has received several regulatory designations relating to its development in AL amyloidosis, including:

* Breakthrough Therapy Designation from the United States Food and Drug Administration;
* Regenerative Medicine Advanced Therapy designation from the FDA;
* Orphan Drug Designation from the FDA; and
* Orphan-drug designation in the European Union from the European Medicines Agency.

These designations support the development and regulatory review of therapies for serious or rare conditions. They do not constitute marketing approval and do not establish that the therapy is safe or effective.

==Research and development milestones==

===2022===
* Initiated and completed a systematic search for advanced cell-therapy programs.
* Licensed global intellectual-property rights relating to NXC-201 from Hadassah in Israel.

===2023–2024===
* Secured orphan-drug and other FDA regulatory designations.
* Continued the ex-United States NEXICART-1 program.
* Reported a 75% complete response rate.
* Received recognition in medical literature addressing AL amyloidosis.

===2025===
* Published clinical research in the ''Journal of Clinical Oncology''.
* Delivered an oral presentation at the American Society of Clinical Oncology annual meeting.
* Presented clinical data at the American Society of Hematology annual meeting.
* Appointed a Chief Commercial Officer as part of preparations for later-stage development and potential commercialization.

===2026===
* Received FDA Breakthrough Therapy Designation for NXC-201.

A potential biologics license application and future commercial launch have been identified as prospective development objectives. These remain forward-looking plans.

==Leadership==

===Ilya Rachman===

'''Ilya M. Rachman, MD, PhD''', is the founder, Chairman and Chief Executive Officer of Immix Biopharma. He has served as Chairman and CEO since the company's founding in 2012 and became Chief Scientific Officer in March 2026.

Rachman received a Bachelor of Science degree from the University of Iowa, a joint MD/PhD degree from the University of Illinois Chicago and an Executive MBA from the University of California, Los Angeles. His doctoral research focused on neuroendocrinology.

Before founding Immix Biopharma, Rachman worked as a physician-scientist at Cedars-Sinai Medical Center and UCLA Health. He also founded a clinical research organization that conducted Phase III and Phase IV studies involving drugs developed by large pharmaceutical companies.

Ilya Rachman is a physician-scientist and cell biologist who oversees Immix Biopharma's corporate direction and scientific mission. He is also named as an inventor on a number of Immix-related patents.

===Gabriel Morris===

'''[[Gabriel Morris]]''' is President, Chief Financial Officer and a director of Immix Biopharma.<ref name="ref11">https://www.prnewswire.com/news-releases/immixbio-announces-gabriel-morris-as-chief-financial-officer-and-a-member-of-the-board-of-directors-301325650.html</ref> He has served as CFO and director since March 2021 and as President since March 2026.

Morris invested in Immix Biopharma before its initial public offering after meeting Rachman in 2020. He later joined the company to oversee finance, corporate development, business development, investor relations, forecasting, budgeting and company operations.

Morris received a Bachelor of Arts in economics from Columbia University in the City of New York in 2008 after also attending Vanderbilt University as a Vanderbilt University College Scholar. As an undergraduate, he participated in the Icahn School of Medicine at Mount Sinai Humanities and Medicine program and conducted experimental scientific research.

From 2008 to 2018, Morris worked on cross-border mergers and acquisitions at Goldman Sachs & Co. and other global investment banks. He participated in more than $50 billion in completed transactions.

From 2019 to 2020, he served as interim Chief Financial Officer of Zap Surgical Systems, where he completed an $81 million growth-equity financing. In 2020, he founded Alwaysraise LLC, a life-sciences investment and advisory firm.

[[Gabriel Morris]] also co-founded Nexcella, Inc., which was involved in the licensing and development pathway associated with NXC-201. He led Immix Biopharma's IPO and subsequent financing transactions totaling more than $250 million.

===Michael Grabow===

'''Michael Grabow''' serves as Chief Commercial Officer of Immix Biopharma. His appointment formed part of the company's preparations for later-stage clinical development and potential commercialization.

==External links==

* [https://immixbio.com Immix Biopharma Official Website]
* [https://www.linkedin.com/company/immix-biopharma/ Immix Biopharma on LinkedIn]
* [https://www.facebook.com/immixbio/ Immix Biopharma on Facebook]
* [https://x.com/immixbio Immix Biopharma on X]

==References==

{{reflist}}

File:Immix Biopharma.jpeg

2026-08-18T07:14:10Z

MrToy:

File:Theron Bassett Arm.jpeg

2026-08-18T07:13:17Z

MrToy:

File:Master of Arts Degree Awarded to Theron Bassett.jpeg

2026-08-18T07:12:47Z

MrToy:

File:CM CERTIFIED Professional MANAGER.png

2026-08-18T07:12:26Z

MrToy:

File:Certificate-life-coach-certification.jpg

2026-08-18T07:11:18Z

MrToy:

Theron Bassett

2026-08-18T07:09:24Z

MrToy: Created page with "{{Infobox person | name = Theron Bassett | image = Theron Bassett.jpeg | birth_date = 2001 | birth_place = Midwest, United States | nationality = American | alma_mater = | occupation = * American Manager * Thought Leader * Life Coach | known_for = * Management *Leadership *Consulting * Founder of the Improve or Death Brand * Veteran of the United States Armed Forces | education = * University..."

{{Infobox person
| name = Theron Bassett
| image = Theron Bassett.jpeg
| birth_date = 2001
| birth_place = Midwest, United States
| nationality = American
| alma_mater =
| occupation =
* American Manager
* Thought Leader
* Life Coach

| known_for =
* Management
*Leadership
*Consulting
* Founder of the Improve or Death Brand
* Veteran of the United States Armed Forces
| education =
* University of Massachusetts Global (MAOL)
* Capella University (MBA)
* Ashworth College (B.S.,A.S.)

 
Potential Candidate for Additional Postgraduate Programs at Various Institutions, pertaining to (M.S., J.D., Ed.D., M.D., Ph.D.)
| website = https://www.theronbassett.com/
}}

[https://www.instagram.com/improveordeath/ '''Theron Bassett'''] is an American manager, veteran, entrepreneur, leadership expert, and founder. He established Improve or Death, a management, cultural, and leadership development brand.

Bassett’s background is related to the demands of directorship, general management, crisis leadership, emergency management, hospitality operations, retail sales management, healthcare administration, residential and community leadership, national brand marketing, property management, asset ownership, and coordinating complex regional operations, as he managed several multimillion-dollar budgets and led dozens of personnel in his early to mid-twenties.<ref>[https://allhiphop.com/uncategorized/meet-theron-bassett/ Meet Theron Bassett] '''Allhiphop'''</ref><ref>[https://apnews.com/press-release/getnews/princeton-ohio-alumnus-theron-bassett-mba-m-a-climbs-as-management-and-classical-liberal-life-coach-amid-support-criticism-09e7492901d725cf80677d54abeb09d4/ princeton-ohio-alumnus-theron-bassett-mba-m-a-climbs-as-management-and-classical-liberal-life-coach-amid-support-criticism] '''AP'''</ref>

Theron Bassett, who in 2026 was ranked in the top 1% of professionals on the business intelligence platform Crunchbase, out of around 2.1 million managers, advisors, and entrepreneurs, became publicly known for management, consulting, and advising.<ref>[https://scoopearth.org/theron-bassett-has-relentless-supporters/ Theron Bassett Has Relentless Supporters] '''ScoopEarth'''</ref><ref>[https://www.windstream.net/finance/category/press/article/pulsebulletin-2026-4-3-who-is-theron-bassett-why-he-has-supporters/ Who Is Theron Bassett? Why He Has Supporters] '''Windstream Finance'''</ref>

Bassett managed large budgets, coached teams, oversaw the transport of multimillion-dollar heavy equipment, and his leadership directly and indirectly impacted thousands of people early in his career.

His online commentary and leadership-focused content on social media in 2025, in which he discussed institutional trust, leadership culture, faith, civic responsibility, social cohesion, and family structure, fueled his early rise.<ref>[https://usaudience.org/theron-bassett-has-critics-why-they-may-have-a-point/ Theron Bassett Has Critics: Why They May Have a Point] '''USAudience'''</ref>

His brand and cultural influence gained national‑level traction on X (formerly Twitter) from 2024 to 2025, where his messaging emphasized institutional integrity, the family unit, and responsible civic engagement through a public perception of welcoming and diverse dialogue. <ref>[https://www.streetinsider.com/Press+Releases/Gen+Z+Thought+Leader+Theron+Bassett+Under+Scrutiny+Claims+We+Aren+a+Generation+of+Complainers+and+Slackers+critics+insist+otherwise./26235204.html/ Gen Z Thought Leader Theron Bassett Under Scrutiny, Claims ‘We Aren’t a Generation of Complainers and Slackers,’ critics insist otherwise] '''Street Insider'''</ref>

As the founder and rights holder of ''Improve or Death'' ([https://x.com/Improveordeath @ImproveOrDeath]), a cultural brand with a mission to “renew urban American exceptionalism,” he promoted inclusive traditional Christianity through synodality and ecumenism, traditional classical liberalism, American exceptionalism, voluntary household patriarchy, and asset and property ownership. The brand also emphasized interfaith dialogue and mutual respect among the Abrahamic faiths while opposing ideological extremism from both the left and the right—a message that garnered [https://x.com/Improveordeath tens of millions of views on X] (formerly Twitter) between 2024 and 2025.<ref>[https://cassiuslife.com/playlist/paul-pierce-marriage-poor-people-women-reactions/item/3/ Paul Pierce Divides The Internet After Saying “Marriage Is For Old People And Poor People” And Only Benefits Women - Page 3] '''Cassiuslife'''</ref>
== Career ==
Theron Bassett's professional career is marked by extensive experience in leadership roles within high-stakes, regulated environments, as well as logistics support, materiel management, and armed security.<ref>[https://entrepreneursbreak.com/theron-bassett-american-manager-gaining-notice-supporters.html/ Theron Bassett: American Manager Gaining Notice; Supporters] '''Entrepreneurs Break'''</ref>
By the age of 24, he guided dozens of personnel in operations, delivered various elements of essential support, was present with patients in critical condition, and carried out armed security duties in high-risk, hostile areas designated for contingency missions, while serving in the United States Armed Forces.<ref>[https://usaudience.org/improve-or-death-founder-theron-bassett-mba-seen-as-a-young-leader-capable-of-coordinating-complex-regional-operations/ Improve or Death Founder Theron Bassett, MBA, Seen as a Young Leader Capable of Coordinating Complex Regional Operations] '''USAudience'''</ref>

Bassett's Improve or Death brand promotes American classical liberalism and, separately, inclusive traditional Christianity—Eastern and Western—garnering over 100 million views on X from 2024 to 2026.<ref>[https://litycoop.com/theron-bassett-an-american-manager/ Theron Bassett An American Manager] '''LityCoop'''</ref><ref>[https://techbullion.com/heres-why-theron-bassett-faces-some-criticism-in-the-media-despite-heavy-support/ Here’s Why Theron Bassett Faces Some Criticism in the Media Despite Heavy Support]'''TechBullion''' </ref><ref> [https://vikenation.org/news/2018/11/15/boys-volleyball-congratulations-to-theron-bassett-for-signing-national-letter-of-intent.aspx Boys Volleyball: Congratulations to Theron Bassett for Signing National Letter of Intent!] '''VIkeNation'''</ref>

Bassett was the only verified Black American professing classical liberalism on Instagram during that period.<ref>[https://techbullion.com/how-much-does-an-american-manager-make/ How Much Does an American Manager Make?] '''Techbullion'''</ref>
The Improve or Death brand emphasizes asset and property ownership.<ref>[https://allhiphop.com/uncategorized/theron-bassetts-podcast-to-emerge-by-2037-promoting-the-urban-american-family-unit/ Theron Bassett’s podcast to emerge by 2037] '''Allhiphop'''</ref>[[File:Theron Bassett Arm.jpeg|thumb|Theron Bassett Taking Up Arms]]
===Military Service===
As an enlisted veteran of the U.S. Navy, Bassett's responsibilities included the supervision of personnel, the administration of operational resources, and the coordination of logistics. <ref>[https://usaudience.org/embrace-classical-liberalism-support-household-patriarchy-win-back-generation-z-men-says-theron-improve-or-death-bassett/ Embrace Classical Liberalism, Support Household Patriarchy, Win Back Generation Z Men, says Theron, “Improve or Death” Bassett] '''USAudience'''</ref><ref>[https://www.slideshare.net/slideshow/theron-a-bassett-ii-announces-release-of-generation-z-leadership-framework/286282986/ Theron A. Bassett II Announces Release of Generation Z Leadership Framework] '''SlideShare'''</ref><ref>[https://scoopearth.org/theron-bassett-an-american-manager/ Theron Bassett: An American Manager] '''ScoopEarth'''</ref><ref>[https://www.facebook.com/allhiphopcom/posts/theron-a-bassett-ii-is-building-a-profile-around-control-under-pressure-and-mult/1425268539644132/ Theron A. Bassett II is building a profile around control under pressure and multiple academic credentials.] '''Facebook'''</ref>
* Oversaw operational budgets between $3 million and $10 million.<ref>[https://www.blogstrove.com/categories/news/who-is-theron-bassett/ Who is Theron Bassett] '''Blogstrove'''</ref>
* Coordinated complex logistics operations—including managing a warehouse with a 10.2-to-50.9-million-dollar inventory or $10.2M-to-$50.9 million-dollar inventory customer support, postal operations, aviation operations, and medical support—while working with patients in critical condition.
* Accumulated between 1,000 and 3,000 hours of armed security duties as a reaction force member standing watch in a Combat Zone Tax Exclusion area.
* Guided 45 to 50+ personnel and separately managed four to six large teams.
===Notable Achievements===
Theron Bassett managed multimillion-dollar budgets—including a $3.2 million budget—and guided over 45 people as a logistician, leading multiple teams prior to the age of 24. He demonstrated specialized expertise in aviation logistics and medical logistics—leading the supply department at an airfield and a medical facility—while managing high-volume mail distribution at a deployed post office (including over 30,000 mail items over several months) and maintaining mission-critical readiness and regulatory compliance. He was awarded multiple citations and medals for meritorious service.<ref>[https://techbullion.com/improve-or-death-founder-theron-bassett-mba-seen-as-a-young-leader-capable-of-coordinating-complex-regional-operations/ Improve or Death Founder Theron Bassett, MBA, Seen as a Young Leader Capable of Coordinating Complex Regional Operations] '''TechBullion'''</ref><ref>[https://dutable.com/how-much-does-an-american-manager-make/ How much Does An American Manager Make?] '''Dutable'''</ref>
===Armed Security in Hostile Environments===
By age 23, he had stood over 1,247 hours—falling within the estimated range of 1,000 to 3,000 hours—of armed security downrange. He credits his experience in diplomacy and armed conflict with developing expertise in organizational leadership, project management, supply chain operations, and interpersonal counseling.<ref>[https://www.bignewsnetwork.com/news/278922328/what-is-a-classical-liberal-who-is-manager-theron-bassett-built-for-regional-management-and-crisis-leadership/ What is a Classical Liberal Who is Manager Theron Bassett Built for Regional Management and Crisis Leadership] '''Big News Network'''</ref><ref>[https://s3.amazonaws.com/contributor-posts/theron-bassett-pictured-amid-high-crunchbase-ranking.html Amazonaws/ Theron-Bassett-pictured-amid-high-Crunchbase-Ranking] '''Amazon AWS'''</ref>

=== Theron Bassett's professional résumé and military service timeline by age 25 ===
Director-level leader with MBA, MAOL, and Lean Six Sigma Master Black Belt, proven in managing multimillion-dollar assets, international operations, and teams of 31 to 45+ personnel in his early twenties.<ref>[https://soapspoiler.com/2024/11/04/the-young-and-the-restless-star-eric-braeden-has-a-message-for-his-female-fans/ The Young and the Restless Star Eric Braeden Has A Message For His Female Fans] '''Soapspoiler'''</ref>

''' Lead, Special Assignment | 2026 (age 25)'''
* Led critical assets, managed complex tasking.<ref>[https://www.msn.com/en-us/money/careersandeducation/how-theron-bassett-of-improve-or-death-demonstrates-generation-zs-strength-in-upper-management-amid-followers-and-critics/ar-AA1WpM8B/ How Theron Bassett of Improve or Death Demonstrates Generation Strength in Upper management Amid Followers and Critics] '''MSN'''</ref>
'''Material Manager, Ad Hoc Director | 2024 – 2026 (age 23 – 25)'''
* Guided over 45 personnel and coordinated operations across multiple locations.<ref>[https://dutable.com/theron-bassett-surpasses-polymarket-founder-shayne-coplan-in-2026-crunchbase-ranking/ Theron Bassett Surpasses Polymarket Founder Shayne Coplan in 2026 Crunchbase Ranking] '''Dutable'''</ref>
* Led 31 personnel executing an enterprise budget of $5.1M–$5.5M and achieved budget targets; managed within a historical program range of $3M–$10M budget ceiling over two years.<ref>[https://sites.google.com/view/meet-theron-bassett/ Meet Theron Bassett] '''Google Site'''</ref>
* Spearheaded a 9-person team for an $11.5 M asset inventory and secure offload of high-value cargo.<ref>[https://www.bignewsnetwork.com/news/279046612/meet-manager-theron-bassett/ Meet Manager Theron Bassett]
'''Big News Network</ref>
* According to his evaluation, he closed the FY25 cycle with a $1.1M reconciliation and a zero-balance ledger—a director-level obligation.<ref>[https://www.focustribune.com/2026/04/princeton-vikings-oh-alumnus-theron-bassett.html?m=1/ Princeton Vikings (OH) Alumnus Theron Bassett c/o ’19 Earns His MBA and Emerges as a Rising American Manager and Organizational Leader] '''Focus Tribune'''</ref>
* Coordinated regional operations, international relations, and general management.
'''Materiel Manager, Group Leader | 2023 – 2024 (age 22 – 23)'''
* Managed a $5.1M asset inventory and a $580K budget, driving a 100% increase in execution efficiency; assisted in Gaza aid response efforts.
* Assisted in 16 operations and 13 evolutions; led teams during supply evolutions as supply lead.<ref>[https://www.mexc.com/news/823576/ Improve or Death Founder Theron Bassett, MBA, Seen as a Young Leader Capable of Coordinating Complex Regional Operations]
'''MEXC'''</ref>
* Held collateral, cabinet-level positions within a professional workforce group.
* Coordinated international relations, regional operations, and general management.
* Managed Defense Priorities and Allocations System (DPAS) designation for critical assets.

'''Postal Lead and General Management | 2023 (age 22)'''
* Managed distribution of  20,000 +  parcels, executing $65 K in secure transactions with zero discrepancies.<ref>[https://techbullion.com/meet-manager-theron-bassett/ Meet Manager Theron Bassett] '''TechBullion'''</ref>
* Qualified 39 personnel, maintaining a 100 % mishap-free operational environment while coordinating transnational collaborations.<ref>[https://www.barchart.com/story/news/832925/american-manager-and-life-coach-theron-a-bassett-ii-pushes-generation-z-leadership-framework/ American Manager and Life Coach Theron Bassett pushes Generation Z leadership Framework] '''Barchart'''</ref>
* Coordinated international relations and general management.<ref>[https://www.alternet.org/bill-maher-new-rules/ Watch: Bill Maher warns 'MAGA crowd cannot be trusted to flirt with dictatorship'] '''AlterNet'''</ref>
'''Armed Security and Team Lead | 2022 (age 21)'''
*  Assisted in safeguarding $1.7 B in mission-critical assets and 900 + joint personnel under strict Anti-Terrorism protocols while coordinating regional operations and international collaborations.<ref>[https://urbanmatter.com/embrace-classical-liberalism-support-household-patriarchy-win-back-generation-z-men-says-theron-improve-or-death-bassett/ Embrace Classical Liberalism, Support Household Patriarchy, Win Back Generation Z Men Says Theron “Improve or Death” Bassett] Urban Matter</ref>
* Instructed 36 personnel in Security Reaction Force tactics with a 100 % graduation rate, stood armed security in hostile environments and aided 350 + contractors.<ref>[https://medium.com/@austin18063281/theron-bassett-has-relentless-supporters-ad2008b8e844/ Theron Bassett Has Relentless Supporters] '''Medium'''</ref>

'''Operational Support | 2019 – 2021 (age 18 – 20)'''
* Delivered operational support across locations, bolstering readiness.
* Responsible for administrative duties.

==Education==
*[https://en.wikipedia.org/wiki/Master_of_Arts/ Master of Arts] in Organizational Leadership (MAOL) from [https://en.wikipedia.org/wiki/University_of_Massachusetts_Global/ University of Massachusetts Global]
*[https://en.wikipedia.org/wiki/Master_of_Business_Administration/ Master of Business Administration] in Project Management (MBA) from [https://www.capella.edu/ Capella University]
*[https://en.wikipedia.org/wiki/Bachelor_of_Science/ Bachelor of Science ] in Business Administration (B.S.) from [https://www.ashworthcollege.edu/ Ashworth College]
*[https://en.wikipedia.org/wiki/Associate_degree/ Associate of Science] in Paralegal Studies (A.S.) from [https://www.ashworthcollege.edu/ Ashworth College]
*[https://www.ashworthcollege.edu/undergraduate-certificates/ College Undergraduate Certificate] in Construction Management from [https://www.ashworthcollege.edu/ Ashworth College]

Potential Candidate for Additional Postgraduate Programs at Various Institutions, pertaining to (M.S., J.D., Ed.D., M.D., Ph.D.) <ref>[https://www.stoneybrookelevators.ca/markets/stocks.php?article=abnewswire-2026-3-13-princeton-ohio-alumnus-theron-bassett-mba-ma-climbs-as-management-and-classical-liberal-life-coach-amid-support-criticism / Princeton (Ohio) Alumnus Theron Bassett, MBA, M.A., Climbs as Management and Classical Liberal Life Coach Amid Support, Criticism] '''Stoney Brook''' </ref>

The Official Theron Bassett is not a CPA.<ref>[https://www.windstream.net/finance/category/press/article/pulsebulletin-2026-4-16-theron-a-bassett-ii-mba-ma-ol-lssmbb-clc-and-m-msi-cm-icpm-navy-veteran-rises-in-management-promoting-inclusive-values/ Theron Bassett MBA, MA (OL), LSSMBB, CLC&M (MSI), CM (ICPM), Navy Veteran, Rises In Management, Promoting Inclusive Values] '''Windstream Finance'''</ref>
[[File:Master of Business Administration, CeDiD- 26RI-7BH6-TMIJ.jpg|thumb|Master of Business Administration Degree Awarded to Theron Bassett]]
[[File:Master_of_Arts_Degree_Awarded_to_Theron_Bassett.jpeg|link=https://wikialpha.co/wiki/File:Master_of_Arts_Degree_Awarded_to_Theron_Bassett.jpeg|thumb|Master of Arts Degree Awarded to Theron Bassett]]
[[File:CM CERTIFIED Professional MANAGER.png|thumb|Certified Manager, awarded by the Institute of Certified Professional Managers]]
===Professional Certifications===
* [https://www.virtualbadge.io/certificate-validator?credential=da66b492-7f96-4e93-8f1d-657979a2b4b2/ Lean Six Sigma Master Black Belt (LSSMBB)]
* Credential ID: '''da66b492-7f96-4e93-8f1d-657979a2b4b2'''
* [https://www.virtualbadge.io/certificate-validator?credential=da66b492-7f96-4e93-8f1d-657979a2b4b2/ Certified Life Coach and Mentor (CLCM or CLC&M)]
* Credential ID: '''deb45f34-3250-4f69-83cb-3a814d3935cc'''
* [https://icpm.net/certification-registry/ Certified Manager (CM)]
* Credential ID: '''215859'''
==Improve or Death==
Bassett established Improve or Death LLC in August 2019 after briefly experiencing homelessness as a young adult in his late teens, serving in the military, and later facing a second brief period of homelessness in his early twenties while working as a reservist and managing mechanical vending machines. By his early to mid-twenties, his brand had gained national recognition on X between 2024 and 2025. Since then, the brand has continued to expand its portfolio of assets and properties.<ref>[https://prophecynewswatch.com/article.cfm?recent_news_id=9611/ Theron Bassett: Improve or Death Christian defends Jewish dignity by synodality] '''Prophecy News Watch'''</ref>
=== Core Positions ===
* Defense of inclusive classical liberalism and traditional Christian synodality.
* Deconstruction of left- and right-wing ideological extremism, radical populism, and strong opposition to antisemitism.
* Promotion of American exceptionalism, cultural normalcy, and interfaith cooperation among Christians, the Jewish people, and Muslims.
* Encouragement of voluntary patriarchal households led by self-disciplined men, complementarian roles, and affirmation of traditional femininity.
* Rejection of partisan tribalism, support for institutional integrity, and advocacy for urban American renewal.
[[File:Certificate-lean-six-sigma-master-black-belt-certification.jpg|link=https://wikialpha.co/wiki/File:Certificate-lean-six-sigma-master-black-belt-certification.jpg|thumb|‎ Lean Six Sigma Master Black Belt Certification Awarded to Theron Bassett]]

== Leadership philosophy and public commentary ==
Theron Bassett has expressed confidence in the people he leads. His public philosophy emphasizes organizational leadership, discipline, and institutional trust. His commentary has frequently focused on personal accountability, emotional discipline, self-governance, and long-term stability within organizations and households.
Bassett has publicly criticized ideological extremism, anti-institutional sentiment, and social polarization.
He has also advocated for interfaith dialogue, responsible civic engagement, and cooperation among diverse social and religious communities.
His public commentary has addressed topics including cultural fragmentation, declining trust in institutions, generational instability, and changing social behaviors among younger generations. Bassett has advocated for long-term leadership, disciplined household structures, economic self-sufficiency, and community stability.
His online presence also features discussions on leadership psychology, emotional regulation, social cohesion, relationship dynamics, and public morality.<ref>[https://www.bignewsnetwork.com/news/279055423/theron-bassett-media-scrutiny-explained-amid-substantial-support/ Theron Bassett Media Scrutiny Explained Amid Substantial Support] '''Big News Network'''</ref>

== Personal Views and Philosophy ==
[[File:Certificate-life-coach-certification.jpg|link=https://wikialpha.co/wiki/File:Certificate-life-coach-certification.jpg|thumb|274x274px|Life Coach Certification Awarded to Theron Bassett]]
Bassett's commentary peaceably opposes both far-right conservative and radical-left progressive ideology while supporting inclusive nonpartisan traditional values and classical liberalism. He has coined the following phrases, each receiving national-level attention on X (formerly Twitter):
* '''[https://x.com/Improveordeath/ "Improve or Death"]''' — 100 million impressions on X.
* '''"We will renew urban American exceptionalism"''' — 100 million impressions on X.<ref>[https://dsnews.co.uk/what-is-a-classical-liberal-who-is-theron-bassett-built-for-regional-management-and-crisis-leadership/ What is a Classical Liberal? Who is Theron Bassett? Built for Regional Management and Crisis Leadership] '''DS NEWS'''</ref>

These widely shared remarks—made in the context of promoting emotional safety, reducing relationship challenges, and combating the damaging narrative of the absentee father in Urban America—promote inclusive, voluntarist, classical American values.

* '''"Voluntary Household Patriarchy"''' — 100 million impressions on X, promoting consensual, voluntary relationships.
* '''[https://x.com/Improveordeath/status/1793013223735632029?s=20/ "To be a wife you have to be selected; we need fathers to teach this."]''' — [https://urbanmatter.com/embrace-classical-liberalism-support-household-patriarchy-win-back-generation-z-men-says-theron-improve-or-death-bassett/ 70 million impressions on X]

Bassett's brand from 2024 to 2025 on X emphasized caution toward populism and anti-institutional sentiment, supporting responsible globalism, traditional household roles, respect for first-wave feminism, family-based provision over state dependency, and concern about moral decline among younger generations. He describes himself as a "repentant, worthless sinner"—not a saint, not an apologist, but sensible.<ref>[https://techbullion.com/theron-bassett-google-search/ Theron Bassett: The Supporters and the Viral Quotes] '''Tech Bullion'''</ref>

Bassett was born a Christian under Gospel-Centered Urban American Catholicism; as an adult, his faith is aligned with Eastern Catholicism, Gospel-oriented Catholicism, and Christian Orthodoxy. Having attended both Orthodox and Catholic churches, he strongly rejects antisemitism and Islamophobia. As a predenominational Christian, Theron Bassett holds profound respect for and alignment with the Catholic and Orthodox traditions, an affinity rooted in his birth into the Catholic Church.

Official statements from Theron Bassett are found exclusively on verified social media accounts bearing his name or his trademark, "Improve Or Death." Any remarks attributed to him from unverified or unknown sources should be considered unofficial.

Disclaimer: This profile is compiled strictly for objective archival and historical reference to document the subject's military service in his early to mid-20s, professional achievements, education, and public commentaries. It does not serve as promotional, marketing, or advertising material.

==Social Media==
* [https://x.com/Improveordeath/'''X''']
* [https://www.instagram.com/improveordeath/'''Instagram''']
* [https://www.linkedin.com/in/theronbassett-who-is-theron-bassett-improve-or-death-improveordeath-theron-bassett-google-bing-panel/'''LinkedIn''']
* [https://www.youtube.com/@ImproveOrDeath/'''YouTube''']
* [https://rumble.com/user/ImproveOrDeath/'''Rumble''']
* [https://www.youtube.com/@ImproveOrDeath/'''YouTube''' (podcast rumored to start by 2036)]
* [https://rumble.com/user/ImproveOrDeath/'''Rumble''' (podcast rumored to start by 2036)]

==External Links==
*[https://www.theronbassett.com/ '''Theron Bassett Personal Website''']
*[https://www.improveordeath.com/ '''Improve or Death Business website''']
*[https://wikitia.com/wiki/Theron_Bassett '''Wikitia''']
*[https://wikialpha.co/wiki/Theron_Bassett '''WikiAlpha''']
*[https://wikigenius.org/wiki/Theron_Bassett '''Wikigenius''']
*[https://en.everybodywiki.com/Theron_Bassett '''EverybodyWiki''']
*[https://filmfreeway.com/TheronBassett2001/ '''FilmFreeway''']
*[https://about.me/theronbassett/'''About Me''']
*[https://www.crunchbase.com/person/theron-bassett-743c '''Crunchbase''']
*[https://www.imdb.com/name/nm18504070/'''IMDb''']
*[https://theronbassett.fandom.com/wiki/Theron_Bassett_Bio'''Fandom''']

== References ==
<references/>

{{good article}}

File:Theron Bassett.jpeg

2026-08-18T07:08:57Z

MrToy:

Gabriel Morris

2026-08-18T05:13:19Z

MrToy: new page created

{{Infobox person
| name = Gabriel Morris
| image = Gabriel Morris.jpeg
| birth_place = United States
| nationality = American
| residence = Los Angeles, California, [[United States]]
| education = Columbia University (B.A. in Economics, 2008); attended Vanderbilt University
| occupation = Biotechnology executive, finance professional, investor
| known_for = President, Chief Financial Officer and Director of [[Immix Biopharma]]
| title = President, Chief Financial Officer and Director
| employer = Immix Biopharma, Inc.
| years_active = 2008–present
| other_positions = Managing Partner, Alwaysraise LLC; Co-founder, Nexcella, Inc.
| board_memberships = Immix Biopharma, Inc.; former board member, Averto Medical, Inc.
| website = http://www.gabriel.bio/
}}

'''Gabriel Morris''' is an American biotechnology executive, investor and finance professional who serves as President, Chief Financial Officer and a Director of [[Immix Biopharma]], Inc. Gabriel has served as Chief Financial Officer and a member of the board since March 2021 and as President since March 2026. Morris has been the Managing Partner of Alwaysraise LLC, a life sciences advisory and investment firm, and a co-founder of Nexcella, Inc.

At [[Immix Biopharma]], Morris co-leads operations and is involved in corporate development, business development, investor relations, financing, forecasting and budgeting. He was moved after meeting founder Ilya Rachman, and invested in [[Immix Biopharma]] before its initial public offering in 2020, and subsequently joined the company as Chief Financial Officer and Director.

== Early life and education ==

Morris grew up in Tennessee, United States. He developed an early interest in science and medicine and published research in the Journal of Biological Chemistry before college. He was admitted to the Icahn School of Medicine at Mount Sinai Humanities and Medicine program, but ultimately pursued a career in biotechnology and finance.

Gabriel attended Vanderbilt University in Tennessee for one year as a Vanderbilt University College Scholar before studying at Columbia University in the City of New York. He earned a Bachelor of Arts in economics in 2008. While at Columbia, he participated in the Icahn School of Medicine at Mount Sinai Humanities and Medicine program as an undergraduate and published experimental research in peer-reviewed scientific journals. His academic recognitions included the Dean’s List and participation in the Columbia Emerging Leaders Program.

== Career ==

=== Investment banking and mergers and acquisitions ===

From 2008 to 2018, Gabriel worked in investment banking, leading cross-border mergers and acquisitions transactions at Goldman Sachs & Co. and other global investment banks.

During this period, he participated in more than US$50 billion in completed transactions, including international mergers and acquisitions and life sciences financing transactions. His work developed experience across strategic transactions, financial structuring, investment and corporate operations.

=== Zap Surgical Systems ===

From 2019 to 2020, Morris served as interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company.

During his tenure, he completed an $81 million growth equity financing round for the company.

=== Alwaysraise LLC ===

In 2020, Morris founded Alwaysraise LLC, a life sciences investment and advisory firm based in San Francisco, California, and has served as its Managing Partner since its founding.

His work through Alwaysraise has focused on life sciences investment, corporate advisory and strategic transactions.

=== Entrepreneurship and board experience ===

Morris has co-founded two companies. One continues to operate independently, while the other was acquired by a Nasdaq-listed company.

His biotechnology and healthcare experience has also included work involving Veris Health and Averto Medical. He previously held a board position at Averto Medical, Inc.

=== [[Immix Biopharma]] ===

Gabriel Morris became involved with Immix Biopharma in 2020 when he invested in the company before its initial public offering after meeting founder Ilya Rachman, MD, PhD.

He later joined Immix Biopharma as Chief Financial Officer and Director in March 2021 and became President in March 2026. His responsibilities include co-leading company operations and overseeing areas including: Corporate development, Business development, Investor relations, Financing, Forecasting, Budgeting & Operational strategy

Morris has led Immix Biopharma’s financing activities, including its initial public offering and subsequent offerings. These financing events have totaled more than $250 million.

His role at Immix combines financial strategy, capital markets experience, business development and operational leadership as the company advances its biotechnology and cell therapy programs.

=== Nexcella ===

He is a co-founder of Nexcella, Inc. Nexcella was involved in licensing the program that became Immix Biopharma’s current lead candidate, NXC-201.

NXC-201 is a sterically optimized BCMA-targeted chimeric antigen receptor T-cell therapy being developed in AL amyloidosis. The therapy incorporates a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. Its therapeutic approach is intended to enable the immune system to recognize and eliminate the plasma cells responsible for producing toxic light chains.

== Biotechnology and healthcare focus ==

Morris’s professional background spans biotechnology, healthcare investment, corporate finance, mergers and acquisitions, business development and public-company operations.

At Immix Biopharma, his activities include financing strategy, investor relations, corporate development and business development in support of the company’s work in AL amyloidosis and cell therapy.

Immix Biopharma’s stated mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures in autoimmune and other indications.

== Leadership and business experience ==

Gabriel Morris has experience working with investors, boards, strategic partners and other stakeholders across biotechnology and financial markets.

His career has included:

* More than a decade in investment banking and mergers and acquisitions;
* More than $50 billion in completed transactions;
* An $81 million growth equity financing at Zap Surgical Systems;
* Leadership of Immix Biopharma’s IPO and subsequent financings totaling more than $250 million;
* Life sciences investing and advisory work through Alwaysraise;
* Biotechnology company formation through Nexcella; and
* Public-company finance, investor relations and operational leadership at Immix Biopharma.

== External links ==

* [http://www.gabriel.bio/ Gabriel Morris Official Website]
* [https://www.linkedin.com/in/gabrielmorrisbio/ Gabriel Morris on LinkedIn]
* [https://scholar.google.com/citations?user=dNJhx_wAAAAJ&hl=en Gabriel Morris Google Scholar Profile]
* [https://x.com/gabrieldotbio Gabriel Morris on X]
* [https://www.linkedin.com/company/nexcella Nexcella on LinkedIn]
* [https://www.linkedin.com/company/immix-biopharma Immix Biopharma on LinkedIn]
{{good article}}